

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:ssspta1623hrr

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2



* * * * * Welcome to STN International * * * * *

NEWS	1	Web Page URLs for STN Seminar Schedule - N. America
NEWS	2	"Ask CAS" for self-help around the clock
NEWS	3 JAN 27	Source of Registration (SR) information in REGISTRY updated and searchable
NEWS	4 JAN 27	A new search aid, the Company Name Thesaurus, available in CA/CaPlus
NEWS	5 FEB 05	German (DE) application and patent publication number format changes
NEWS	6 MAR 03	MEDLINE and LMedline reloaded
NEWS	7 MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS	8 MAR 03	FRANCEPAT now available on STN
NEWS	9 MAR 29	Pharmaceutical Substances (PS) now available on STN
NEWS	10 MAR 29	WPIFV now available on STN
NEWS	11 MAR 29	New monthly current-awareness alert (SDI) frequency in RAPRA
NEWS	12 APR 26	PROMT: New display field available
NEWS	13 APR 26	IFIPAT/IFIUDB/IFICDB: New super search and display field available
NEWS	14 APR 26	LITAlert now available on STN
NEWS	15 APR 27	NLDB: New search and display fields available
NEWS	16 May 10	PROUSDDR now available on STN
NEWS	17 May 19	PROUSDDR: One FREE connect hour, per account, in both May and June 2004
NEWS	18 May 12	EXTEND option available in structure searching
NEWS	19 May 12	Polymer links for the POLYLINK command completed in REGISTRY
NEWS	20 May 17	FRFULL now available on STN
NEWS EXPRESS	MARCH 31	CURRENT WINDOWS VERSION IS V7.00A, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 26 APRIL 2004
NEWS HOURS		STN Operating Hours Plus Help Desk Availability
NEWS INTER		General Internet Information
NEWS LOGIN		Welcome Banner and News Items
NEWS PHONE		Direct Dial and Telecommunication Network Access to STN
NEWS WWW		CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

299

FILE 'HOME' ENTERED AT 15:30:31 ON 26 MAY 2004

=> file registry
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 15:30:42 ON 26 MAY 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 25 MAY 2004 HIGHEST RN 685826-98-6
DICTIONARY FILE UPDATES: 25 MAY 2004 HIGHEST RN 685826-98-6

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

Please note that search-term pricing does apply when
conducting SmartSELECT searches.


Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>
Uploading C:\STNEXP4\QUERIES\10660439.str

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



open to
any 2 group
or
cation

Structure attributes must be viewed using STN Express query preparation.

=> s l1 full

FULL SEARCH INITIATED 15:31:03 FILE 'REGISTRY'
 FULL SCREEN SEARCH COMPLETED - 164 TO ITERATE

100.0% PROCESSED 164 ITERATIONS
 SEARCH TIME: 00.00.01


85 ANSWERS

L2 85 SEA SSS FUL L1

=> d 1-85 l2

L2 ANSWER 1 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 556808-14-1 REGISTRY
 CN Phosphoric acid, mono(3-chlorophenyl) mono[2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl] ester, ammonium salt (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C24 H24 Cl O8 P . H3 N
 SR CA
 LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER
 DT.CA Caplus document type: Journal
 RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation)

Double bond geometry as shown.




● NH₃

1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 2 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 556808-13-0 REGISTRY
 CN Phosphoric acid, monocyclohexyl mono[2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl] ester, ammonium salt (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C24 H31 O8 P . H3 N
 SR CA
 LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER
 DT.CA Caplus document type: Journal
 RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation)

Double bond geometry as shown.




● NH₃

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 3 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN
RN 556808-12-9 REGISTRY
CN Phosphoric acid, mono[2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl] mono(2,2,2-trifluoroethyl) ester, ammonium salt (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C20 H22 F3 O8 P . H3 N
SR CA
LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER
DT.CA Caplus document type: Journal
RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation)

Double bond geometry as shown.




● NH₃

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 4 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN
RN 556808-11-8 REGISTRY
CN Phosphoric acid, dibutyl 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl ester (9CI) (CA INDEX NAME)
FS STEREOSEARCH

MF C26 H37 O8 P
 SR CA
 LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER
 DT.CA Caplus document type: Journal
 RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation)

Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 5 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 556808-10-7 REGISTRY
 CN Phosphoric acid, diethyl 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl ester (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C22 H29 O8 P
 SR CA
 LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER
 DT.CA Caplus document type: Journal
 RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation)

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 6 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 556808-09-4 REGISTRY
 CN Phosphoric acid, 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl dimethyl ester (9CI) (CA INDEX NAME)
 FS STEREOSEARCH

299

MF C20 H25 O8 P
SR CA
LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER
DT.CA Caplus document type: Journal
RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation)

Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 7 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN
RN 519060-38-9 REGISTRY
CN 1,4-Benzenediol, 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, bis(dihydrogen phosphate), tetrasodium salt (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C18 H22 O12 P2 . 4 Na
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
DT.CA Caplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); USES (Uses)

Double bond geometry as shown.



● 4 Na

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 8 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN
RN 519060-35-6 REGISTRY
CN Phosphoric acid, 2-cyanoethyl 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl methyl ester (9CI) (CA INDEX NAME)
FS STEREOSEARCH

299

MF C22 H26 N O8 P


SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

DT.CA Caplus document type: Patent

RL.P Roles from patents: PREP (Preparation); RACT (Reactant or reagent)

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 9 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN

RN 519060-19-6 REGISTRY

CN 1,2-Benzenediol, 4-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, bis(dihydrogen phosphate), tetrasodium salt (9CI) (CA INDEX NAME)

FS STEREOSEARCH

MF C17 H20 O11 P2 . 4 Na


SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

DT.CA Caplus document type: Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

Double bond geometry as shown.



● 4 Na

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 10 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN

RN 519060-15-2 REGISTRY


CN Phenol, 2,6-dimethoxy-3-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, dihydrogen phosphate, disodium salt (9CI) (CA INDEX NAME)

FS STEREOSEARCH

MF C19 H23 O9 P . 2 Na

SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
 DT.CA Caplus document type: Patent
 RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

Double bond geometry as shown.




● 2 Na

1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 11 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 519060-10-7 REGISTRY
 CN Phenol, 2-bromo-6-methoxy-3-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, dihydrogen phosphate, disodium salt (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C18 H20 Br O8 P . 2 Na
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
 DT.CA Caplus document type: Patent
 RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

Double bond geometry as shown.




● 2 Na

1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 12 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 519060-07-2 REGISTRY
 CN Phosphoric acid, mono[2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl] monomethyl ester, ammonium salt (9CI) (CA INDEX NAME)
 FS STEREOSEARCH

MF C19 H23 O8 P . H3 N
 SR CA
 LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL
 DT.CA Caplus document type: Journal; Patent
 RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)
 RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation)

Double bond geometry as shown.




● NH₃

2 REFERENCES IN FILE CA (1907 TO DATE)
 2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 13 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 519060-01-6 REGISTRY
 CN 1,2-Benzenediol, 3-methoxy-6-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, 2,2'-(hydrogen phosphate), monosodium salt (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C36 H39 O14 P . Na
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
 DT.CA Caplus document type: Patent
 RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

Double bond geometry as shown.




● Na

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 14 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 519060-00-5 REGISTRY
 CN Phenol, 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, hydrogen phosphate, sodium salt (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C36 H39 O12 P . Na
 SR CA
 LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL
 DT.CA Caplus document type: Journal; Patent
 RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)
 RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation)

Double bond geometry as shown.




● Na

2 REFERENCES IN FILE CA (1907 TO DATE)

2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 15 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 519059-99-5 REGISTRY
 CN Phosphoric acid, mono[2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl] monoethyl ester, ammonium salt (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C26 H37 O8 P . H3 N
 SR CA
 LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL
 DT.CA Caplus document type: Journal; Patent
 RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)
 RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation)

Double bond geometry as shown.




● NH₃

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 16 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN
RN 519059-97-3 REGISTRY
CN 1,3-Benzenediol, 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, bis(dihydrogen phosphate), tetrasodium salt (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C18 H22 O12 P2 . 4 Na
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
DT.CA Caplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

Double bond geometry as shown.



● 4 Na

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L2 ANSWER 17 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN
RN 404886-35-7 REGISTRY
CN Glycine, ethyl ester, compd. with 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl dihydrogen phosphate (1:1) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C18 H21 O8 P . C4 H9 N O2
SR CA
LC STN Files: CA, CAPLUS, USPAT2, USPATFULL
DT.CA Caplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)

299

CM 1


CRN 222030-63-9
CMF C18 H21 O8 P

Double bond geometry as shown.



CM 2

CRN 459-73-4
CMF C4 H9 N O2




1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 18 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN
RN 404886-34-6 REGISTRY
CN Glycine, methyl ester, compd. with 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl dihydrogen phosphate (1:1) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C18 H21 O8 P . C3 H7 N O2
SR CA
LC STN Files: CA, CAPLUS, USPAT2, USPATFULL
DT.CA Caplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)

CM 1


CRN 222030-63-9
CMF C18 H21 O8 P

Double bond geometry as shown.



CM 2

CRN 616-34-2
CMF C3 H7 N O2




1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 19 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN
RN 404886-33-5 REGISTRY
CN L-Histidine, compd. with 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl dihydrogen phosphate (1:1) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C18 H21 O8 P . C6 H9 N3 O2
SR CA
LC STN Files: CA, CAPLUS, USPAT2, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)

CM 1

CRN 222030-63-9
CMF C18 H21 O8 P


Double bond geometry as shown.



CM 2

CRN 71-00-1
CMF C6 H9 N3 O2

Absolute stereochemistry. Rotation (-).



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 20 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN
RN 404886-32-4 REGISTRY


299

CN 1,3-Propanediol, 2-amino-2-(hydroxymethyl)-, compd. with
2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl dihydrogen
phosphate (1:1) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C18 H21 O8 P . C4 H11 N O3
SR CA
LC STN Files: CA, CAPLUS, USPAT2, USPATFULL
DT.CA Caplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PRP
(Properties); USES (Uses)

CM 1


CRN 222030-63-9
CMF C18 H21 O8 P

Double bond geometry as shown.



CM 2

CRN 77-86-1
CMF C4 H11 N O3




1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 21 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN
RN 400014-99-5 REGISTRY
CN Butanoic acid, 2-amino-4-[[imino(nitroamino)methyl]amino]-, methyl ester,
(2S)-, compd. with 2-methoxy-5-[(1Z)-2-(3,4,5-
trimethoxyphenyl)ethenyl]phenyl dihydrogen phosphate (2:1) (9CI) (CA
INDEX NAME)
FS STEREOSEARCH
MF C18 H21 O8 P . 2 C6 H13 N5 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
DT.CA Caplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES
(Uses)

CM 1

CRN 400014-98-4
CMF C6 H13 N5 O4


Absolute stereochemistry.



CM 2

CRN 222030-63-9
CMF C18 H21 O8 P


Double bond geometry as shown.



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 22 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN
RN 391671-20-8 REGISTRY
CN Phenol, 2-methoxy-5-[(1E)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, dihydrogen
phosphate (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C18 H21 O8 P
CI COM
SR CA
LC STN Files: CA, CAPLUS, CASREACT, USPATFULL
DT.CA Caplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES
(Uses)


Double bond geometry as shown.



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 23 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN
RN 391671-18-4 REGISTRY
CN Phenol, 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, dihydrogen phosphate, monopotassium salt (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C18 H21 O8 P . K
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA Caplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)
CRN (222030-63-9)

Double bond geometry as shown.



● K


1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 24 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN
RN 391671-17-3 REGISTRY
CN Phenol, 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, dihydrogen phosphate, manganese salt (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C18 H21 O8 P . Mn
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA Caplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

CM 1

CRN 222030-63-9
CMF C18 H21 O8 P

Double bond geometry as shown.



CM 2

CRN 7439-96-5

CMF Mn

Mn

1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L2 ANSWER 25 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 380892-83-1 REGISTRY
 CN 3-Pyridinecarboxamide, compd. with 2,3-dimethoxy-5-[(1Z)-2-[4-methoxy-3-(phosphonooxy)phenyl]ethenyl]phenyl phosphate (2:1) (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C17 H20 O11 P2 . 2 C6 H6 N2 O
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
 DT.CA Caplus document type: Journal; Patent
 RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)
 RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)

CM 1

CRN 380892-79-5

CMF C17 H20 O11 P2


Double bond geometry as shown.



CM 2

CRN 98-92-0

CMF C6 H6 N2 O




2 REFERENCES IN FILE CA (1907 TO DATE)
 2 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L2 ANSWER 26 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN

RN 380892-82-0 REGISTRY
 CN Phenol, 2,3-dimethoxy-5-[(1Z)-2-[4-methoxy-3-(phosphonooxy)phenyl]ethenyl]-
 , dihydrogen phosphate, compd. with morpholine (1:2) (9CI) (CA INDEX
 NAME)
 FS STEREOSEARCH
 MF C17 H20 O11 P2 . 2 C4 H9 N O
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
 DT.CA Caplus document type: Journal; Patent
 RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PRP
 (Properties); USES (Uses)
 RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation);
 PRP (Properties); USES (Uses)
 CM 1
 CRN 380892-79-5
 CMF C17 H20 O11 P2

Double bond geometry as shown.



CM 2
 CRN 110-91-8
 CMF C4 H9 N O



2 REFERENCES IN FILE CA (1907 TO DATE)
 2 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L2 ANSWER 27 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 380892-81-9 REGISTRY
 CN Cinchonan-9-ol, 6'-methoxy-, (9S)-, compd. with 2,3-dimethoxy-5-[(1Z)-2-[4-
 methoxy-3-(phosphonooxy)phenyl]ethenyl]phenyl phosphate (2:1) (salt) (9CI)
 (CA INDEX NAME)
 FS STEREOSEARCH
 MF C20 H24 N2 O2 . 1/2 C17 H20 O11 P2
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
 DT.CA Caplus document type: Journal; Patent
 RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PRP
 (Properties); USES (Uses)
 RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation);
 PRP (Properties); USES (Uses)

299

CM 1

CRN 380892-79-5
CMF C17 H20 O11 P2


Double bond geometry as shown.



CM 2

CRN 56-54-2
CMF C20 H24 N2 O2

Absolute stereochemistry. Rotation (+).



2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L2 ANSWER 28 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN
RN 380892-80-8 REGISTRY
CN Cinchonan-9-ol, 6'-methoxy-, (8 α ,9R)-, compd. with
2,3-dimethoxy-5-[(1Z)-2-[4-methoxy-3-(phosphonooxy)phenyl]ethenyl]phenyl
phosphate (2:1) (salt) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C20 H24 N2 O2 . 1/2 C17 H20 O11 P2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
DT.CA Caplus document type: Journal; Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PRP
(Properties); USES (Uses)
RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation);
PRP (Properties); USES (Uses)

CM 1

CRN 380892-79-5
CMF C17 H20 O11 P2

Double bond geometry as shown.


299



CM 2

CRN 130-95-0
CMF C20 H24 N2 O2


Absolute stereochemistry.



2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 29 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN
RN 380892-79-5 REGISTRY
CN Phenol, 2,3-dimethoxy-5-[(1Z)-2-[4-methoxy-3-(phosphonooxy)phenyl]ethenyl]-
, dihydrogen phosphate (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C17 H20 O11 P2
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
DT.CA Caplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); RACT
(Reactant or reagent); USES (Uses)

Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 30 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 380892-78-4 REGISTRY
 CN Phenol, 2,3-dimethoxy-5-[(1Z)-2-[4-methoxy-3-(phosphonooxy)phenyl]ethenyl]-
 , dihydrogen phosphate, magnesium salt (1:2) (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C17 H20 O11 P2 . 2 Mg
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
 DT.CA Caplus document type: Journal; Patent
 RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PRP
 (Properties); USES (Uses)
 RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation);
 PRP (Properties); USES (Uses)
 CRN (380892-79-5)

Double bond geometry as shown.




● 2 Mg

2 REFERENCES IN FILE CA (1907 TO DATE)
 2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 31 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 380892-77-3 REGISTRY
 CN Phenol, 2,3-dimethoxy-5-[(1Z)-2-[4-methoxy-3-(phosphonooxy)phenyl]ethenyl]-
 , dihydrogen phosphate, manganese(2+) salt (1:2) (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C17 H20 O11 P2 . 2 Mn
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
 DT.CA Caplus document type: Journal; Patent
 RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PRP
 (Properties); USES (Uses)
 RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation);
 PRP (Properties); USES (Uses)
 CRN (380892-79-5)

Double bond geometry as shown.




● 2 Mn(II)

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 32 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN
RN 380892-76-2 REGISTRY
CN Phenol, 2,3-dimethoxy-5-[(1Z)-2-[4-methoxy-3-(phosphonooxy)phenyl]ethenyl]-
, dihydrogen phosphate, zinc salt (1:2) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C17 H20 O11 P2 . 2 Zn
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
DT.CA Caplus document type: Journal; Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PRP
(Properties); USES (Uses)
RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation);
PRP (Properties); USES (Uses)
CRN (380892-79-5)

Double bond geometry as shown.




● 2 Zn

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 33 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN
RN 380892-75-1 REGISTRY
CN Phenol, 2,3-dimethoxy-5-[(1Z)-2-[4-methoxy-3-(phosphonooxy)phenyl]ethenyl]-
, dihydrogen phosphate, calcium salt (1:2) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C17 H20 O11 P2 . 2 Ca
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
DT.CA Caplus document type: Journal; Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PRP
(Properties); USES (Uses)
RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation);
PRP (Properties); USES (Uses)
CRN (380892-79-5)

Double bond geometry as shown.




● 2 Ca

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 34 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN
RN 380892-74-0 REGISTRY
CN Phenol, 2,3-dimethoxy-5-[(1Z)-2-[4-methoxy-3-(phosphonooxy)phenyl]ethenyl]-, dihydrogen phosphate, dirubidium salt (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C17 H20 O11 P2 . 2 Rb
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
DT.CA Caplus document type: Journal; Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)
RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)
CRN (380892-79-5)

Double bond geometry as shown.



● 2 Rb


2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 35 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN
RN 380892-73-9 REGISTRY
CN Phenol, 2,3-dimethoxy-5-[(1Z)-2-[4-methoxy-3-(phosphonooxy)phenyl]ethenyl]-, dihydrogen phosphate, dipotassium salt (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C17 H20 O11 P2 . 2 K
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
DT.CA Caplus document type: Journal; Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)
RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)

299

CRN (380892-79-5)

Double bond geometry as shown.



● 2 K

2 REFERENCES IN FILE CA (1907 TO DATE)

2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 36 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN

RN 380892-72-8 REGISTRY

CN Phenol, 2,3-dimethoxy-5-[(1Z)-2-[4-methoxy-3-(phosphonooxy)phenyl]ethenyl]-, dihydrogen phosphate, dilithium salt (9CI) (CA INDEX NAME)

FS STEREOSEARCH

MF C17 H20 O11 P2 . 2 Li

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL


DT.CA CAPLUS document type: Journal; Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)

RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)

CRN (380892-79-5)

Double bond geometry as shown.



● 2 Li

2 REFERENCES IN FILE CA (1907 TO DATE)

2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 37 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN

RN 380892-71-7 REGISTRY

CN Phenol, 2,3-dimethoxy-5-[(1Z)-2-[4-methoxy-3-(phosphonooxy)phenyl]ethenyl]-, dihydrogen phosphate, disodium salt (9CI) (CA INDEX NAME)

FS STEREOSEARCH

MF C17 H20 O11 P2 . 2 Na


SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

DT.CA CAPLUS document type: Journal; Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)
 RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)
 CRN (380892-79-5)

Double bond geometry as shown.




● 2 Na

2 REFERENCES IN FILE CA (1907 TO DATE)
 2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 38 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 380892-70-6 REGISTRY
 CN Phosphoric acid, (1Z)-1,2-ethenediylbis(6-methoxy-3,1-phenylene) tetrakis(phenylmethyl) ester (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C45 H44 O11 P2
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
 DT.CA Caplus document type: Journal; Patent
 RL.P Roles from patents: PREP (Preparation); RACT (Reactant or reagent)
 RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
 2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 39 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN

RN 313693-43-5 REGISTRY

CN 1,2-Benzenediol, 3-methoxy-6-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, bis(dihydrogen phosphate), compd. with 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxyisoquinoline (1:4) (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Isoquinoline, 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-, compd. with 3-methoxy-6-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-1,2-phenylene bis(dihydrogen phosphate) (4:1) (9CI)

FS STEREOSEARCH

MF C20 H21 N O4 . 1/4 C18 H22 O12 P2

SR CA

LC STN Files: CA, CAPLUS, IMSRESEARCH, TOXCENTER, USPATFULL

DT.CA CAPLUS document type: Journal; Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)


RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

CM 1

CRN 288847-35-8

CMF C18 H22 O12 P2 .


Double bond geometry as shown.



CM 2

CRN 58-74-2

CMF C20 H21 N O4



2 REFERENCES IN FILE CA (1907 TO DATE)


2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 40 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 313693-42-4 REGISTRY
 CN Benzeneacetonitrile, α -[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]-3,4-dimethoxy- α -(1-methylethyl)-, compd. with 3-methoxy-6-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-1,2-phenylene bis(dihydrogen phosphate) (4:1) (9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN 1,2-Benzenediol, 3-methoxy-6-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, bis(dihydrogen phosphate), compd. with α -[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]-3,4-dimethoxy- α -(1-methylethyl)benzeneacetonitrile (1:4) (9CI)
 FS STEREOSEARCH
 MF C27 H38 N2 O4 . 1/4 C18 H22 O12 P2
 SR CA
 LC STN Files: CA, CAPLUS, IMSRESEARCH, TOXCENTER, USPATFULL
 DT.CA Caplus document type: Journal; Patent
 RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)
 RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

CM 1


CRN 288847-35-8
 CMF C18 H22 O12 P2

Double bond geometry as shown.



CM 2

CRN 52-53-9
 CMF C27 H38 N2 O4



2 REFERENCES IN FILE CA (1907 TO DATE)
 2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 41 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 313692-49-8 REGISTRY
 CN Cinchonan-9-ol, 6'-methoxy-, (9S)-, compd. with 3-methoxy-6-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-1,2-phenylene bis(dihydrogen phosphate) (4:1)

(9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 1,2-Benzenediol, 3-methoxy-6-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, bis(dihydrogen phosphate), compd. with (9S)-6'-methoxycinchonan-9-ol (1:4) (9CI)

FS STEREOSEARCH

MF C20 H24 N2 O2 . 1/4 C18 H22 O12 P2

SR CA

LC STN Files: CA, CAPLUS, IMSRESEARCH, TOXCENTER, USPATFULL

DT.CA Caplus document type: Journal; Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)


RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

CM 1

CRN 288847-35-8

CMF C18 H22 O12 P2

Double bond geometry as shown.




CM 2

CRN 56-54-2

CMF C20 H24 N2 O2

Absolute stereochemistry. Rotation (+).



2 REFERENCES IN FILE CA (1907 TO DATE)

2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 42 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN

RN 313692-48-7 REGISTRY

CN Cinchonan-9-ol, 6'-methoxy-, (8 α ,9R)-, compd. with 3-methoxy-6-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-1,2-phenylene bis(dihydrogen phosphate) (4:1) (9CI) (CA INDEX NAME)


OTHER CA INDEX NAMES:

CN 1,2-Benzenediol, 3-methoxy-6-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, bis(dihydrogen phosphate), compd. with (8 α ,9R)-6'-methoxycinchonan-9-ol (1:4) (9CI)
 FS STEREOSEARCH
 MF C20 H24 N2 O2 . 1/4 C18 H22 O12 P2
 SR CA
 LC STN Files: CA, CAPLUS, IMSRESEARCH, TOXCENTER, USPATFULL
 DT.CA Caplus document type: Journal; Patent
 RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)
 RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

CM 1

CRN 288847-35-8
 CMF C18 H22 O12 P2


Double bond geometry as shown.



CM 2

CRN 130-95-0
 CMF C20 H24 N2 O2

Absolute stereochemistry.



2 REFERENCES IN FILE CA (1907 TO DATE)
 2 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L2 ANSWER 43 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 313692-47-6 REGISTRY
 CN 1,2-Benzenediol, 3-methoxy-6-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, bis(dihydrogen phosphate), compd. with morpholine (1:4) (9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:

CN Morpholine, compd. with 3-methoxy-6-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-1,2-phenylene bis(dihydrogen phosphate) (4:1) (9CI)
 FS STEREOSEARCH
 MF C18 H22 O12 P2 . 4 C4 H9 N O
 SR CA
 LC STN Files: CA, CAPLUS, IMSRESEARCH, TOXCENTER, USPATFULL
 DT.CA Caplus document type: Journal; Patent
 RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)
 RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

CM 1


CRN 288847-35-8
 CMF C18 H22 O12 P2

Double bond geometry as shown.



CM 2


CRN 110-91-8
 CMF C4 H9 N O



2 REFERENCES IN FILE CA (1907 TO DATE)
 2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 44 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 313692-46-5 REGISTRY
 CN 1,2-Benzenediol, 3-methoxy-6-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, bis(dihydrogen phosphate), zinc salt (1:2) (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C18 H22 O12 P2 . 2 Zn
 SR CA
 LC STN Files: CA, CAPLUS, IMSRESEARCH, TOXCENTER, USPATFULL
 DT.CA Caplus document type: Journal; Patent
 RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)
 RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); USES (Uses)
 CRN (288847-35-8)

Double bond geometry as shown.




● 2 Zn

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 45 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN
RN 313692-45-4 REGISTRY
CN 1,2-Benzenediol, 3-methoxy-6-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, bis(dihydrogen phosphate), manganese(2+) salt (1:2) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C18 H22 O12 P2 . 2 Mn
SR CA
LC STN Files: CA, CAPLUS, IMSRESEARCH, TOXCENTER, USPATFULL
DT.CA Caplus document type: Journal; Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)
RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); USES (Uses)
CRN (288847-35-8)

Double bond geometry as shown.




● 2 Mn(II)

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 46 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN
RN 313692-44-3 REGISTRY
CN 1,2-Benzenediol, 3-methoxy-6-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, bis(dihydrogen phosphate), calcium salt (1:2) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C18 H22 O12 P2 . 2 Ca

SR CA
 LC STN Files: CA, CAPLUS, IMSRESEARCH, TOXCENTER, USPATFULL
 DT.CA CAPLUS document type: Journal; Patent
 RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)
 RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); USES (Uses)
 CRN (288847-35-8)

Double bond geometry as shown.




● 2 Ca

2 REFERENCES IN FILE CA (1907 TO DATE)
 2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 47 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 313692-43-2 REGISTRY
 CN 1,2-Benzenediol, 3-methoxy-6-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, bis(dihydrogen phosphate), magnesium salt (1:2) (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C18 H22 O12 P2 . 2 Mg
 SR CA
 LC STN Files: CA, CAPLUS, IMSRESEARCH, TOXCENTER, USPATFULL
 DT.CA CAPLUS document type: Journal; Patent
 RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)
 RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); USES (Uses)
 CRN (288847-35-8)

Double bond geometry as shown.




● 2 Mg

2 REFERENCES IN FILE CA (1907 TO DATE)

2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 48 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 313692-42-1 REGISTRY
 CN 1,2-Benzenediol, 3-methoxy-6-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, bis(dihydrogen phosphate), tetracesium salt (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C18 H22 O12 P2 . 4 Cs
 SR CA
 LC STN Files: CA, CAPLUS, IMSRESEARCH, TOXCENTER, USPATFULL
 DT.CA Caplus document type: Journal; Patent
 RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)
 RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); USES (Uses)
 CRN (288847-35-8)

Double bond geometry as shown.




● 4 Cs

2 REFERENCES IN FILE CA (1907 TO DATE)
 2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 49 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 313692-41-0 REGISTRY
 CN 1,2-Benzenediol, 3-methoxy-6-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, bis(dihydrogen phosphate), tetrapotassium salt (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C18 H22 O12 P2 . 4 K
 SR CA
 LC STN Files: CA, CAPLUS, IMSRESEARCH, TOXCENTER, USPATFULL
 DT.CA Caplus document type: Journal; Patent
 RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)
 RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); USES (Uses)
 CRN (288847-35-8)

Double bond geometry as shown.




● 4 K

2 REFERENCES IN FILE CA (1907 TO DATE)

2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 50 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 313692-39-6 REGISTRY
 CN 1,2-Benzenediol, 3-methoxy-6-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, bis(dihydrogen phosphate), tetralithium salt (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C18 H22 O12 P2 . 4 Li
 SR CA
 LC STN Files: CA, CAPLUS, CASREACT, IMSRESEARCH, TOXCENTER, USPATFULL
 DT.CA Caplus document type: Journal; Patent
 RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)
 RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); USES (Uses)
 CRN (288847-35-8)

Double bond geometry as shown.



● 4 Li


2 REFERENCES IN FILE CA (1907 TO DATE)

2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 51 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 313692-37-4 REGISTRY
 CN Phosphoric acid, 3-methoxy-6-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-1,2-phenylene tetraethyl ester (9CI) (CA INDEX NAME)
 OTHER NAMES:
 CN 2',3'-O-Di[bisethylphosphoryl]combretastatin A1
 FS STEREOSEARCH
 MF C26 H38 O12 P2
 SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
 DT.CA Caplus document type: Journal; Patent
 RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)
 RL.NP Roles from non-patents: PREP (Preparation)

Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
 2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 52 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 313692-35-2 REGISTRY
 CN Phosphoric acid, 3-methoxy-6-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-1,2-phenylene tetrakis(phenylmethyl) ester (9CI) (CA INDEX NAME)
 OTHER NAMES:
 CN (Z)-2-(2,3-Bis((bis(benzyloxy)phosphinyl)oxy)-4-methoxyphenyl)-1-(3,4,5-trimethoxyphenyl)ethene
 CN 2',3'-O-Di[bisbenzylphosphoryl]combretastatin A1
 FS STEREOSEARCH
 MF C46 H46 O12 P2
 SR CA
 LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL
 DT.CA Caplus document type: Journal; Patent
 RL.P Roles from patents: PREP (Preparation); RACT (Reactant or reagent)
 RL.NP Roles from non-patents: PREP (Preparation); RACT (Reactant or reagent)

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 53 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN
RN 288847-37-0 REGISTRY
CN 3-Pyridinecarboxamide, compd. with 3-methoxy-6-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-1,2-phenylene bis(dihydrogen phosphate) (4:1) (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 1,2-Benzenediol, 3-methoxy-6-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, bis(dihydrogen phosphate), compd. with 3-pyridinecarboxamide (1:4) (9CI)
FS STEREOSEARCH
MF C18 H22 O12 P2 . 4 C6 H6 N2 O
SR CA
LC STN Files: CA, CAPLUS, IMSRESEARCH, TOXCENTER, USPATFULL
DT.CA Caplus document type: Journal; Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

CM 1


CRN 288847-35-8
CMF C18 H22 O12 P2

Double bond geometry as shown.



CM 2

CRN 98-92-0
CMF C6 H6 N2 O



3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 54 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN
RN 288847-36-9 REGISTRY

CN 1,2-Benzenediol, 3-methoxy-6-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, bis(dihydrogen phosphate), compd. with piperazine (1:2) (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Piperazine, compd. with 3-methoxy-6-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-1,2-phenylene bis(dihydrogen phosphate) (2:1) (9CI)

FS STEREOSEARCH

MF C18 H22 O12 P2 . 2 C4 H10 N2

SR CA

LC STN Files: CA, CAPLUS, IMSRESEARCH, TOXCENTER, USPATFULL

DT.CA Caplus document type: Journal; Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)


RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

CM 1

CRN 288847-35-8

CMF C18 H22 O12 P2


Double bond geometry as shown.



CM 2

CRN 110-85-0

CMF C4 H10 N2



3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 55 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN

RN 288847-35-8 REGISTRY

CN 1,2-Benzenediol, 3-methoxy-6-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, bis(dihydrogen phosphate) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN Oxi 4503

FS STEREOSEARCH


MF C18 H22 O12 P2

CI COM

299

SR CA
LC STN Files: CA, CAPLUS, IMSRESEARCH, PROUSDDR, SYNTHLINE, TOXCENTER
DT.CA Caplus document type: Journal
RL.NP Roles from non-patents: BIOL (Biological study); USES (Uses)

Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 56 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN
RN 288847-34-7 REGISTRY
CN 1,2-Benzenediol, 3-methoxy-6-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, bis(dihydrogen phosphate), tetrasodium salt (9CI) (CA INDEX NAME)
OTHER NAMES:
CN Combretastatin A-1 phosphate
FS STEREOSEARCH
MF C18 H22 O12 P2 . 4 Na
SR CA
LC STN Files: BIOSIS, CA, CAPLUS, CASREACT, EMBASE, IMSRESEARCH, PROUSDDR, SYNTHLINE, TOXCENTER, USPATFULL
DT.CA Caplus document type: Journal; Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PROC (Process); PRP (Properties); USES (Uses)
RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); USES (Uses)
CRN (288847-35-8)

Double bond geometry as shown.



● 4 Na

8 REFERENCES IN FILE CA (1907 TO DATE)


8 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 57 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 229178-48-7 REGISTRY
 CN Benzeneacetonitrile, α -[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]-3,4-dimethoxy- α -(1-methylethyl)-, compd. with 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl dihydrogen phosphate (1:1) (9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN Phenol, 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, dihydrogen phosphate, compd. with α -[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]-3,4-dimethoxy- α -(1-methylethyl)benzeneacetonitrile (1:1) (9CI)
 FS STEREOSEARCH
 MF C27 H38 N2 O4 . C18 H21 O8 P
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
 DT.CA CAPLUS document type: Journal; Patent
 RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)
 RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)

CM 1


CRN 222030-63-9
 CMF C18 H21 O8 P

Double bond geometry as shown.



CM 2

CRN 52-53-9
 CMF C27 H38 N2 O4



3 REFERENCES IN FILE CA (1907 TO DATE)
 3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 58 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 229178-47-6 REGISTRY
 CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aS,5aS,6S,12aS)-,

compd. with 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl dihydrogen phosphate (1:1) (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Phenol, 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, dihydrogen phosphate, compd. with (4S,4aS,5aS,6S,12aS)-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide (1:1) (9CI)

FS STEREOSEARCH

MF C22 H24 N2 O8 . C18 H21 O8 P

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

DT.CA Caplus document type: Journal; Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)


RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)

CM 1

CRN 222030-63-9

CMF C18 H21 O8 P

Double bond geometry as shown.




CM 2

CRN 60-54-8

CMF C22 H24 N2 O8

Absolute stereochemistry. Rotation (-).



3 REFERENCES IN FILE CA (1907 TO DATE)

3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 59 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN

RN 229178-46-5 REGISTRY

CN Cinchonan-9-ol, 6'-methoxy-, (9S)-, compd. with 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl dihydrogen phosphate (1:1) (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:


CN Phenol, 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, dihydrogen

phosphate, compd. with (9S)-6'-methoxycinchonan-9-ol (1:1) (9CI)
 FS STEREOSEARCH
 MF C20 H24 N2 O2 . C18 H21 O8 P
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
 DT.CA Caplus document type: Journal; Patent
 RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)
 RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)

CM 1

CRN 222030-63-9
 CMF C18 H21 O8 P


Double bond geometry as shown.



CM 2

CRN 56-54-2
 CMF C20 H24 N2 O2

Absolute stereochemistry. Rotation (+).



3 REFERENCES IN FILE CA (1907 TO DATE)
 3 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L2 ANSWER 60 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 229178-45-4 REGISTRY
 CN Cinchon-9-ol, 6'-methoxy-, (8 α ,9R)-, compd. with
 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl dihydrogen
 phosphate (1:1) (9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN Phenol, 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, dihydrogen
 phosphate, compd. with (8 α ,9R)-6'-methoxycinchonan-9-ol (1:1) (9CI)
 FS STEREOSEARCH
 MF C20 H24 N2 O2 . C18 H21 O8 P
 SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
 DT.CA CAplus document type: Journal; Patent
 RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)
 RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)

CM 1

CRN 222030-63-9
 CMF C18 H21 O8 P


Double bond geometry as shown.



CM 2

CRN 130-95-0
 CMF C20 H24 N2 O2

Absolute stereochemistry.



3 REFERENCES IN FILE CA (1907 TO DATE)
 3 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L2 ANSWER 61 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 229178-43-2 REGISTRY
 CN D-Glucose, 2-amino-2-deoxy-, compd. with 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl dihydrogen phosphate (1:1) (9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN Phenol, 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, dihydrogen phosphate, compd. with 2-amino-2-deoxy-D-glucose (1:1) (9CI)
 FS STEREOSEARCH
 MF C18 H21 O8 P . C6 H13 N O5
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
 DT.CA CAplus document type: Journal; Patent
 RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation);
PRP (Properties); USES (Uses)

CM 1

CRN 222030-63-9
CMF C18 H21 O8 P


Double bond geometry as shown.



CM 2

CRN 3416-24-8
CMF C6 H13 N O5

Absolute stereochemistry. Rotation (+).



3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 62 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN
RN 229178-42-1 REGISTRY

CN Cinchonan-9-ol, (9S)-, compd. with 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl dihydrogen phosphate (1:1) (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Phenol, 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, dihydrogen phosphate, compd. with (9S)-cinchonan-9-ol (1:1) (9CI)

FS STEREOSEARCH

MF C19 H22 N2 O . C18 H21 O8 P

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

DT.CA Caplus document type: Journal; Patent


RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation);
PRP (Properties); USES (Uses)

CM 1

CRN 222030-63-9
CMF C18 H21 O8 P

Double bond geometry as shown.




CM 2

CRN 118-10-5

CMF C19 H22 N2 O

Absolute stereochemistry. Rotation (+).



3 REFERENCES IN FILE CA (1907 TO DATE)

3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 63 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN

RN 229178-41-0 REGISTRY

CN Adenosine, compd. with 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl dihydrogen phosphate (1:1) (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Phenol, 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, dihydrogen phosphate, compd. with adenosine (1:1) (9CI)

FS STEREOSEARCH

MF C18 H21 O8 P . C10 H13 N5 O4

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

DT.CA Caplus document type: Journal; Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)


CM 1

CRN 222030-63-9

CMF C18 H21 O8 P

Double bond geometry as shown.

299




CM 2

CRN 58-61-7

CMF C10 H13 N5 O4

Absolute stereochemistry.



3 REFERENCES IN FILE CA (1907 TO DATE)

3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 64 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN

RN 229178-40-9 REGISTRY

CN Phenol, 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, dihydrogen phosphate, compd. with pyridine (1:1) (9CI) (CA INDEX NAME).

FS STEREOSEARCH

MF C18 H21 O8 P . C5 H5 N

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

DT.CA Caplus document type: Journal; Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)


RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)

CM 1

CRN 222030-63-9


CMF C18 H21 O8 P

Double bond geometry as shown.



CM 2

CRN 110-86-1
 CMF C5 H5 N




3 REFERENCES IN FILE CA (1907 TO DATE)
 3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 65 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 229178-39-6 REGISTRY
 CN Phenol, 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, dihydrogen phosphate, compd. with 1H-pyrazole (1:1) (9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN 1H-Pyrazole, compd. with 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl dihydrogen phosphate (1:1) (9CI)
 FS STEREOSEARCH
 MF C18 H21 O8 P . C3 H4 N2
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
 DT.CA Caplus document type: Journal; Patent
 RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)
 RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)

CM 1


CRN 222030-63-9
 CMF C18 H21 O8 P

Double bond geometry as shown.



CM 2

CRN 288-13-1
 CMF C3 H4 N2




3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 66 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN
RN 229178-38-5 REGISTRY
CN Phenol, 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, dihydrogen phosphate, compd. with piperidine (1:1) (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Piperidine, compd. with 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl dihydrogen phosphate (1:1) (9CI)
FS STEREOSEARCH
MF C18 H21 O8 P . C5 H11 N
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
DT.CA Caplus document type: Journal; Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)
RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)

CM 1


CRN 222030-63-9
CMF C18 H21 O8 P

Double bond geometry as shown.



CM 2

CRN 110-89-4
CMF C5 H11 N



3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L2 ANSWER 67 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN
RN 229178-37-4 REGISTRY
CN Phenol, 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, dihydrogen phosphate, compd. with piperazine (1:1) (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Piperazine, compd. with 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl dihydrogen phosphate (1:1) (9CI)
FS STEREOSEARCH
MF C18 H21 O8 P . C4 H10 N2
SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
 DT.CA CAplus document type: Journal; Patent
 RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)
 RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)

CM 1


CRN 222030-63-9
 CMF C18 H21 O8 P

Double bond geometry as shown.



CM 2

CRN 110-85-0
 CMF C4 H10 N2




3 REFERENCES IN FILE CA (1907 TO DATE)
 3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 68 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 229178-36-3 REGISTRY
 CN Phenol, 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, dihydrogen phosphate, compd. with morpholine (1:1) (9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN Morpholine, compd. with 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl dihydrogen phosphate (1:1) (9CI)
 FS STEREOSEARCH
 MF C18 H21 O8 P . C4 H9 N O
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
 DT.CA CAplus document type: Journal; Patent
 RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)
 RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)

CM 1

CRN 222030-63-9
 CMF C18 H21 O8 P


Double bond geometry as shown.



CM 2

CRN 110-91-8

CMF C4 H9 N O



3 REFERENCES IN FILE CA (1907 TO DATE)

3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 69 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN

RN 229178-35-2 REGISTRY

CN Phenol, 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, dihydrogen phosphate, compd. with 1H-imidazole (1:1) (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 1H-Imidazole, compd. with 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl dihydrogen phosphate (1:1) (9CI)

FS STEREOSEARCH

MF C18 H21 O8 P . C3 H4 N2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

DT.CA Caplus document type: Journal; Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)


RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)

CM 1

CRN 222030-63-9

CMF C18 H21 O8 P


Double bond geometry as shown.



CM 2

CRN 288-32-4

CMF C3 H4 N2




3 REFERENCES IN FILE CA (1907 TO DATE)

3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 70 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 229178-31-8 REGISTRY
 CN Phenol, 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, dihydrogen phosphate, monolithium salt (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C18 H21 O8 P . Li
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
 DT.CA CAplus document type: Journal; Patent
 RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)
 RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)
 CRN (222030-63-9)

Double bond geometry as shown.



● Li

3 REFERENCES IN FILE CA (1907 TO DATE)


3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 71 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 229178-30-7 REGISTRY
 CN Phenol, 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, dihydrogen phosphate, monocation salt (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C18 H21 O8 P . Cs
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
 DT.CA CAplus document type: Journal; Patent
 RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)
 RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)

299

CRN (222030-63-9)

Double bond geometry as shown.




● Cs

3 REFERENCES IN FILE CA (1907 TO DATE)

3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 72 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN
RN 229178-29-4 REGISTRY
CN Phenol, 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, dihydrogen phosphate, calcium salt (1:1) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C18 H21 O8 P . Ca
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
DT.CA CAplus document type: Journal; Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)
RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)
CRN (222030-63-9)

Double bond geometry as shown.



● Ca

3 REFERENCES IN FILE CA (1907 TO DATE)

3 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L2 ANSWER 73 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN
RN 229178-28-3 REGISTRY
CN Phenol, 2-methoxy-5-[(1E)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, dihydrogen phosphate, disodium salt (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C18 H21 O8 P . 2 Na
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
DT.CA CAplus document type: Journal; Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

RL.NP Roles from non-patents: BIOL (Biological study); USES (Uses)

CRN (391671-20-8)

Double bond geometry as shown.



● 2 Na

2 REFERENCES IN FILE CA (1907 TO DATE)

2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 74 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN

RN 229178-27-2 REGISTRY

CN Phosphoric acid, 2-methoxy-5-[(1E)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl bis(phenylmethyl) ester (9CI) (CA INDEX NAME)

FS STEREOSEARCH

MF C32 H33 O8 P

SR CA


LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

DT.CA Caplus document type: Journal; Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

RL.NP Roles from non-patents: PREP (Preparation); RACT (Reactant or reagent)

Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 75 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN
RN 226989-84-0 REGISTRY
CN Phenol, 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, dihydrogen phosphate, monosodium salt (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C18 H21 O8 P . Na
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
DT.CA Caplus document type: Journal; Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)
RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)
CRN (222030-63-9)

Double bond geometry as shown.




● Na

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 76 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN
RN 222030-63-9 REGISTRY
CN Phenol, 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, dihydrogen phosphate (9CI) (CA INDEX NAME)
OTHER NAMES:

CN Combretastatin A4 phosphate
 FS STEREOSEARCH
 MF C18 H21 O8 P
 CI COM
 SR CA
 LC STN Files: BIOSIS, CA, CAPLUS, CASREACT, EMBASE, IMSRESEARCH, PROUSDDR,
 TOXCENTER, USPAT2, USPATFULL
 DT.CA Caplus document type: Conference; Journal; Patent
 RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PROC
 (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)
 RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological
 study); USES (Uses)

Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

38 REFERENCES IN FILE CA (1907 TO DATE)
 39 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 77 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 208465-89-8 REGISTRY
 CN Phosphoric acid, 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl
 1 bis[2-(trimethylsilyl)ethyl] ester (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C28 H45 O8 P Si2
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
 DT.CA Caplus document type: Journal; Patent
 RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); RACT
 (Reactant or reagent); USES (Uses)
 RL.NP Roles from non-patents: PREP (Preparation); RACT (Reactant or reagent)

Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)

2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 78 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 208465-88-7 REGISTRY
 CN Phosphoric acid, 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl bis(phenylmethyl) ester (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C32 H33 O8 P
 SR CA
 LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL
 DT.CA Caplus document type: Journal; Patent
 RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 RL.NP Roles from non-patents: PREP (Preparation); RACT (Reactant or reagent)

Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)
 3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 79 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 174909-45-6 REGISTRY
 CN Phosphoric acid, bis(1,1-dimethylethyl) 2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl ester, (E)- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C26 H37 O8 P
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER
 DT.CA Caplus document type: Journal
 RL.NP Roles from non-patents: PREP (Preparation)

Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 80 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN
RN 174909-40-1 REGISTRY
CN Phenol, 2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)ethenyl]-, dihydrogen phosphate, diammonium salt, (Z)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C18 H21 O8 P . 2 H3 N
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER
DT.CA Caplus document type: Journal
RL.NP Roles from non-patents: PREP (Preparation); RACT (Reactant or reagent)
CRN (222030-63-9)

Double bond geometry as shown.




● 2 NH₃

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 81 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN
RN 168555-66-6 REGISTRY
CN Phenol, 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, dihydrogen phosphate, disodium salt (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Phenol, 2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)ethenyl]-, dihydrogen phosphate, disodium salt, (Z)-
OTHER NAMES:

CN CA 4P
 CN Combretastatin A4 disodium phosphate
 FS STEREOSEARCH
 DR 229027-07-0
 MF C18 H21 O8 P . 2 Na
 SR CA
 LC STN Files: BIOSIS, CA, CAPLUS, CASREACT, EMBASE, IMSDRUGNEWS,
 IMSRESEARCH, PROUSDDR, TOXCENTER, USPAT2, USPATFULL
 DT.CA Caplus document type: Dissertation; Journal; Patent
 RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PROC
 (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)
 RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation);
 PROC (Process); USES (Uses)
 RLD.NP Roles for non-specific derivatives from non-patents: BIOL (Biological
 study); PREP (Preparation)
 CRN (222030-63-9)

Double bond geometry as shown.




● 2 Na

51 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 53 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 82 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 168555-65-5 REGISTRY
 CN Phosphoric acid, 2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl
 bis(2,2,2-trichloroethyl) ester, (Z)- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C22 H23 Cl6 O8 P
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
 DT.CA Caplus document type: Journal; Patent
 RL.P Roles from patents: PREP (Preparation); RACT (Reactant or reagent)
 RL.NP Roles from non-patents: PREP (Preparation); RACT (Reactant or reagent)

Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 83 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN
RN 145545-17-1 REGISTRY
CN Phenol, 2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)ethenyl]-, dihydrogen
phosphate, dipotassium salt, (Z)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C18 H21 O8 P . 2 K
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
DT.CA Caplus document type: Journal; Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PRP
(Properties); USES (Uses)
RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation)
CRN (222030-63-9)

Double bond geometry as shown.




● 2 K

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 84 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN
RN 145545-16-0 REGISTRY
CN Phenol, 2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)ethenyl]-, dihydrogen
phosphate, monoammonium salt, (Z)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C18 H21 O8 P . H3 N
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
DT.CA Caplus document type: Journal; Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); RACT
(Reactant or reagent); USES (Uses)

RL.NP Roles from non-patents: PREP (Preparation); RACT (Reactant or reagent)
 CRN (222030-63-9)

Double bond geometry as shown.




● NH₃

3 REFERENCES IN FILE CA (1907 TO DATE)
 3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 85 OF 85 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 145545-15-9 REGISTRY
 CN Phosphoric acid, bis(1,1-dimethylethyl) 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl ester (9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN Phosphoric acid, bis(1,1-dimethylethyl) 2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl ester, (Z)-
 FS STEREOSEARCH
 MF C26 H37 O8 P
 SR CA
 LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL
 DT.CA Caplus document type: Journal; Patent
 RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 RL.NP Roles from non-patents: PREP (Preparation); RACT (Reactant or reagent)

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

5 REFERENCES IN FILE CA (1907 TO DATE)
 5 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	306.29	306.50

FILE 'CAPLUS' ENTERED AT 15:31:47 ON 26 MAY 2004
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 26 May 2004 VOL 140 ISS 22
 FILE LAST UPDATED: 25 May 2004 (20040525/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l2
 L3 99 L2

=> d 1-99 bib abs l3
 'ABSL3' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

The following are valid formats:

ABS ----- GI and AB
 ALL ----- BIB, AB, IND, RE
 APPS ----- AI, PRAI
 BIB ----- AN, plus Bibliographic Data and PI table (default)
 CAN ----- List of CA abstract numbers without answer numbers
 CBIB ----- AN, plus Compressed Bibliographic Data
 DALL ----- ALL, delimited (end of each field identified)
 DMAX ----- MAX, delimited for post-processing
 FAM ----- AN, PI and PRAI in table, plus Patent Family data
 FBIB ----- AN, BIB, plus Patent FAM
 IND ----- Indexing data
 IPC ----- International Patent Classifications
 MAX ----- ALL, plus Patent FAM, RE
 PATS ----- PI, SO
 SAM ----- CC, SX, TI, ST, IT
 SCAN ----- CC, SX, TI, ST, IT (random display, no answer numbers;
 SCAN must be entered on the same line as the DISPLAY,
 e.g., D SCAN or DISPLAY SCAN)
 STD ----- BIB, IPC, and NCL

IABS ----- ABS, indented with text labels
 IALL ----- ALL, indented with text labels
 IBIB ----- BIB, indented with text labels
 IMAX ----- MAX, indented with text labels
 ISTD ----- STD, indented with text labels

OBIB ----- AN, plus Bibliographic Data (original)

OIBIB ----- OIBB, indented with text labels

SBIB ----- BIB, no citations

SIBIB ----- IBIB, no citations

HIT ----- Fields containing hit terms

HITIND ----- IC, ICA, ICI, NCL, CC and index field (ST and IT)
containing hit terms

HITRN ----- HIT RN and its text modification

HITSTR ----- HIT RN, its text modification, its CA index name, and
its structure diagram

HITSEQ ----- HIT RN, its text modification, its CA index name, its
structure diagram, plus NTE and SEQ fields

FHITSTR ----- First HIT RN, its text modification, its CA index name, and
its structure diagram

FHITSEQ ----- First HIT RN, its text modification, its CA index name, its
structure diagram, plus NTE and SEQ fields

KWIC ----- Hit term plus 20 words on either side

OCC ----- Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field codes. For a list of the display field codes, enter HELP DFIELDS at an arrow prompt (=>). Examples of formats include: TI; TI,AU; BIB,ST; TI,IND; TI,SO. You may specify the format fields in any order and the information will be displayed in the same order as the format specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR, FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC to view a specified Accession Number.

ENTER DISPLAY FORMAT (BIB):bib

L3 ANSWER 1 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2004:386630 CAPLUS

TI Methods for quantifying ratio between two nucleic acids by NASBA for
diagnosis and treatment of HIV-1, tumor or angiogenic disorders

IN Timmermans, Eveline Catherina Anna Clasina; Van Gemen, Bob

PA Primagen Holding B.V., Neth.

SO Eur. Pat. Appl., 32 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1418242	A1	20040512	EP 2003-78547	20031107
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	EP 1418241	A1	20040512	EP 2002-79673	20021108
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
PRAI	EP 2002-79673	A	20021108		
	US 2002-425055P	P	20021108		

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2004:386629 CAPLUS

TI Methods for quantifying ratio between two nucleic acids by NASBA for
diagnosis and treatment of HIV-1, tumor or angiogenic disorders

IN Timmermans, Eveline Catherina Anna Clasina; Van Gemen, Bob

PA Primagen Holding B.V., Neth.

SO Eur. Pat. Appl., 37 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1418241	A1	20040512	EP 2002-79673	20021108
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK			
	EP 1418242	A1	20040512	EP 2003-78547	20031107
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
	WO 2004042085	A2	20040521	WO 2003-NL780	20031107
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM			
	RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRAI EP 2002-79673 A 20021108

US 2002-425055P P 20021108

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2004:371961 CAPLUS

TI Combretastatin A4 phosphate

AU West, Catharine M. L.; Price, Pat

CS Academic Department of Radiation Oncology and Manchester Molecular Imaging
Centre, University of Manchester, Christie NHS Trust Hospital, Manchester,
M20 4BX, UK

SO Anti-Cancer Drugs (2004), 15(3), 179-187

CODEN: ANTDEV; ISSN: 0959-4973

PB Lippincott Williams & Wilkins

DT Journal; General Review

LA English

RE.CNT 83 THERE ARE 83 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2004:157469 CAPLUS

DN 140:210743

TI Compositions and methods for treating cancer using maytansinoid CD44
antibody immunoconjugates and chemotherapeutic agents

IN Adolf, Guenther; Baum, Anke; Heider, Karl-Heinz

PA Boehringer Ingelheim International GmbH, Germany

SO Eur. Pat. Appl., 52 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1391213	A1	20040225	EP 2002-18686	20020821
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK			

WO 2004018000 A2 20040304 WO 2003-EP9166 20030819

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC,
NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG

PRAI EP 2002-18686 A 20020821

OS MARPAT 140:210743

RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 5 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2003:905546 CAPLUS

DN 140:192442

TI Antitumor activity of TZT-1027 (Soblidotin) against vascular endothelial
growth factor-secreting human lung cancer in vivo

AU Natsume, Tsugitaka; Watanabe, Jun-ichi; Koh, Yasuhiro; Fujio, Nami; Ohe,
Yuichiro; Horiuchi, Toshi; Saijo, Nagahiro; Nishio, Kazuto; Kobayashi,
Motohiro

CS Medicinal Research Department, Teikoku Hormone Mfg. Co., Ltd., Kanagawa,
213-8522, Japan

SO Cancer Science (2003), 94(9), 826-833
CODEN: CSACCM; ISSN: 1347-9032

PB Japanese Cancer Association

DT Journal

LA English

RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 6 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2003:836866 CAPLUS

DN 139:337828

TI Preparation of resveratrol and sodium resverastatin phosphate derivatives
for use in pharmaceutical compositions as antineoplastic and antimicrobial
agents

IN Pettit, George R.; Grealish, Matthew P.

PA Arizona Board of Regents, USA

SO PCT Int. Appl., 51 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003086414	A1	20031023	WO 2003-US11008	20030410

W: CA, JP, US

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IT, LU, MC, NL, PT, RO, SE, SI, SK, TR

PRAI US 2002-371782P P 20020410

OS CASREACT 139:337828

RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 7 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2003:779807 CAPLUS

DN 140:121898

TI Ocular neovascularization: a valuable model system
AU Campochiaro, Peter Anthony; Hackett, Sean Francis
CS The Departments of Ophthalmology and Neuroscience, The Johns Hopkins
University School of Medicine, Baltimore, MD, 21287-9277, USA
SO Oncogene (2003), 22(42), 6537-6548
CODEN: ONCNES; ISSN: 0950-9232
PB Nature Publishing Group
DT Journal; General Review
LA English
RE.CNT 133 THERE ARE 133 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 8 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:704282 CAPLUS
DN 140:122251
TI The vascular targeting agent combretastatin A-4-phosphate induces
neutrophil recruitment to endothelial cells in vitro
AU Brooks, Andrew C.; Kanthou, Chryso; Cook, Ian H.; Tozer, Gillian M.;
Barber, Paul R.; Vojnovic, Boris; Nash, Gerard B.; Parkins, Charles S.
CS Tumour Microcirculation Group, Mount Vernon Hospital, Gray Cancer
Institute, Northwood, Middx., HA6 2JR, UK
SO Anticancer Research (2003), 23(4), 3199-3206
CODEN: ANTRD4; ISSN: 0250-7005
PB International Institute of Anticancer Research
DT Journal
LA English
RE.CNT 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 9 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:684303 CAPLUS
DN 140:52580
TI Antiangiogenesis and radiotherapy: What is the role of combined modality
treatment?
AU Classen, Johannes; Budach, Wilfried
CS Dep. Radiation Oncology, Tuebingen University, Tuebingen, D-72076, Germany
SO Current Medicinal Chemistry: Anti-Cancer Agents (2003), 3(5), 375-382
CODEN: CMCACI; ISSN: 1568-0118
PB Bentham Science Publishers Ltd.
DT Journal; General Review
LA English
RE.CNT 56 THERE ARE 56 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 10 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:649793 CAPLUS
DN 140:87178
TI Efficacy of the tumour vascular targeting agent combretastatin A-4-P at
clinically relevant doses
AU Tozer, G. M.; Honess, D. J.; Wilson, J.; Hill, S. A.; Hodgkiss, R. J.;
Ameer-Beg, S.; Vojnovic, B.; Prise, V. E.
CS Gray Cancer Institute, Mount Vernon Hospital, Northwood, UK
SO Microcirculation and Vascular Biology, Meeting of the European Society for
Microcirculation, 22nd, Exeter, United Kingdom, Aug. 28-30, 2002 (2002),
43-47. Editor(s): Tooke, John; Shore, Angela; Whatmore, Jacqueline.
Publisher: Monduzzi Editore, Bologna, Italy.
CODEN: 69EIUX; ISBN: 88-323-2828-3
DT Conference
LA English
RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 11 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:649791 CAPLUS
DN 140:70488
TI Nitrotyrosination of endothelial α -tubulin: potential effects on
binding of the tumour vascular-targeting agent, combretastatin A-4-P
AU Parkins, C. S.; Cook, I. H.; Kanthou, C.; Mapp, P.; Tozer, G. M.
CS Tumour Microcirculation Group, Gray Cancer Institute, Northwood, UK
SO Microcirculation and Vascular Biology, Meeting of the European Society for
Microcirculation, 22nd, Exeter, United Kingdom, Aug. 28-30, 2002 (2002),
33-37. Editor(s): Tooke, John; Shore, Angela; Whatmore, Jacqueline.
Publisher: Monduzzi Editore, Bologna, Italy.
CODEN: 69EIUX; ISBN: 88-323-2828-3
DT Conference
LA English
RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 12 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:649789 CAPLUS
DN 140:266851
TI Effect of radiation and combretastatin A-4-P on cellular localisation of
hypoxia inducible factor 1
AU Dachs, G. U.; Kanthou, C.; Tozer, G. M.
CS Tumour Microcirculation Group, Gray Cancer Institute, Mount Vernon
Hospital, Northwood, UK
SO Microcirculation and Vascular Biology, Meeting of the European Society for
Microcirculation, 22nd, Exeter, United Kingdom, Aug. 28-30, 2002 (2002),
19-23. Editor(s): Tooke, John; Shore, Angela; Whatmore, Jacqueline.
Publisher: Monduzzi Editore, Bologna, Italy.
CODEN: 69EIUX; ISBN: 88-323-2828-3
DT Conference
LA English
RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 13 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:535620 CAPLUS
DN 140:12606
TI Combretastatin A-1 phosphate potentiates the antitumour activity of
cisplatin in a murine adenocarcinoma model
AU Shnyder, S. D.; Cooper, P. A.; Pettit, G. R.; Lippert, J. W., III; Bibby,
M. C.
CS Cancer Research Unit, Tom Connors Cancer Research Centre, University of
Bradford, Bradford, BD7 1DP, UK
SO Anticancer Research (2003), 23(2B), 1619-1623
CODEN: ANTRD4; ISSN: 0250-7005
PB International Institute of Anticancer Research
DT Journal
LA English
RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 14 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:535566 CAPLUS
DN 139:390868
TI Oxi4503, a novel vascular targeting agent: effects on blood flow and
antitumor activity in comparison to combretastatin A-4 phosphate
AU Hua, Jianyi; Sheng, Yezhou; Pinney, Kevin G.; Garner, Charles M.; Kane,
Robert R.; Prezioso, Joseph A.; Pettit, George R.; Chaplin, David J.;
Edvardsen, Klaus
CS Department of Cell and Molecular Biology, Section for Tumor Immunology,
University of Lund, Lund, 22184, Swed.

SO Anticancer Research (2003), 23(2B), 1433-1440
CODEN: ANTRD4; ISSN: 0250-7005
PB International Institute of Anticancer Research
DT Journal
LA English
RE.CNT 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 15 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:488339 CAPLUS
DN 139:390448
TI Heme oxygenase and the novel tumour-specific anti-vascular compound
combretastatin A4-phosphate
AU Khelifi, Amel F.; Prise, Vivien E.; Foresti, Roberta; Clark, James E.;
Kanthou, Chryso; Motterlini, Roberto; Tozer, Gillian M.
CS Gray Cancer Institute, Mount Vernon Hospital, Northwood, Middlesex, HA6
2JR, UK
SO Heme Oxygenase in Biology and Medicine (2002), 303-312. Editor(s):
Abraham, Nader G.; Alam, Jawed; Nath, Karl. Publisher: Kluwer
Academic/Plenum Publishers, New York, N. Y.
CODEN: 69ECI3; ISBN: 0-306-47264-3
DT Conference; General Review
LA English
RE.CNT 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 16 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:376404 CAPLUS
DN 138:362737
TI Methods for treating neoplastic, angiogenic, vascular, fibroblastic,
and/or immunosuppressive irregularities of the eye and/or joint via
administration of combretastatin based medicaments, and iontophoretic
devices for delivering combretastatin based medicaments
IN Parkinson, Thomas M.; Szlek, Malgorzata; Lloyd, Lindsay B.; Vollmer, David
L.
PA USA
SO U.S. Pat. Appl. Publ., 12 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003092774	A1	20030515	US 2002-270273	20021011
PRAI	US 2001-330212P	P	20011017		
OS	MARPAT 138:362737				

L3 ANSWER 17 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:334852 CAPLUS
DN 138:353746
TI Preparation of stilbenes as vascular targeting agents (VTAs) for treatment
of solid tumors and retinal neovascularization.
IN Chaplin, David J.; Garner, Charles Manly, III; Kane, Robert Ronald;
Pinney, Kevin G.; Prezioso, Joseph Anthony
PA Oxigene, Inc., USA; Evardsen, Klaus
SO PCT Int. Appl., 56 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----

PI WO 2003035008 A2 20030501 WO 2002-US34497 20021028
 WO 2003035008 A3 20031113

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,
 TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
 CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
 PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
 NE, SN, TD, TG

US 2003149003 A1 20030807 US 2002-281528 20021028
 PRAI US 2001-337348P P 20011026
 OS MARPAT 138:353746

L3 ANSWER 18 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2003:301800 CAPLUS
 DN 139:159587
 TI Vascular targeting effect of combretastatin A-4 phosphate dominates the
 inherent angiogenesis inhibitory activity
 AU Ahmed, Bisan; van Eijk, Loes I.; Bouma-ter Steege, Jessica C. A.; van der
 Schaft, Daisy W. J.; van Esch, Anita M.; Joosten-Achjanie, Susan R.;
 Lambin, Philippe; Landuyt, Willy; Griffioen, Arjan W.
 CS Angiogenesis Laboratory, Research Institute for Growth and Development
 (GROW), Department of Internal Medicine, University Hospital Maastricht,
 Maastricht, 6202 AZ, Neth.
 SO International Journal of Cancer (2003), 105(1), 20-25
 CODEN: IJCNW; ISSN: 0020-7136
 PB Wiley-Liss, Inc.
 DT Journal
 LA English
 RE.CNT 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 19 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2003:293586 CAPLUS
 DN 139:85159
 TI Synthesis, in vitro, and in vivo evaluation of phosphate ester derivatives
 of combretastatin A-4
 AU Hadimani, Mallinath B.; Hua, Jianyi; Jonklaas, M. Devan; Kessler, Raymond
 J.; Sheng, Yezhou; Olivares, Adrian; Tanpure, Rajendra P.; Weiser, Aimee;
 Zhang, Jianxing; Edvardsen, Klaus; Kane, Robert R.; Pinney, Kevin G.
 CS Department of Chemistry & Biochemistry and Center for Drug Discovery,
 Baylor University, Waco, TX, 76798-7348, USA
 SO Bioorganic & Medicinal Chemistry Letters (2003), 13(9), 1505-1508
 CODEN: BMCLE8; ISSN: 0960-894X
 PB Elsevier Science B.V.
 DT Journal
 LA English
 OS CASREACT 139:85159
 RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 20 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2003:284080 CAPLUS
 DN 139:285853
 TI Activity of the vascular targeting agent combretastatin A-4 disodium
 phosphate in a xenograft model of AIDS-associated Kaposi's sarcoma
 AU Rojiani, Amyn M.; Li, Lingyun; Rise, Leroy; Siemann, Dietmar W.
 CS Department of Interdisciplinary Oncology and Department of Pathology, H.

Lee Moffitt Cancer Center and Research Institute, University of South
Florida, Tampa, FL, USA
SO Acta Oncologica (2002), 41(1), 98-105
CODEN: ACTOEL; ISSN: 0284-186X
PB Taylor & Francis Ltd.
DT Journal
LA English
RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 21 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:284079 CAPLUS
DN 139:30186
TI Preclinical evaluations of therapies combining the vascular targeting
agent combretastatin A-4 disodium phosphate and conventional anticancer
therapies in the treatment of Kaposi's sarcoma
AU Li, Lingyun; Rojiani, Aryn M.; Siemann, Dietmar W.
CS Department of Pharmacology and Experimental Therapeutics, Shands Cancer
Center, University of Florida, Gainesville, FL, 32610, USA
SO Acta Oncologica (2002), 41(1), 91-97
CODEN: ACTOEL; ISSN: 0284-186X
PB Taylor & Francis Ltd.
DT Journal
LA English
RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 22 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:202525 CAPLUS
DN 138:243276
TI Vascular implants containing combretastatin A-4 or combretastatin A-4
phosphate
IN Wnendt, Stephan; Chaplin, David; Kuttler, Bernd; Lorenz, Guenter
PA Oxygene Inc., USA
SO PCT Int. Appl., 61 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003020331	A1	20030313	WO 2002-EP9836	20020903
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10142897	A1	20030320	DE 2001-10142897	20010903
DE 10142881	A1	20030403	DE 2001-10142881	20010903
PRAI DE 2001-10142881	A	20010903		
DE 2001-10142897	A	20010903		

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 23 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:145065 CAPLUS
DN 139:288187

TI Enhancement of radiation therapy by vascular targeting agents
AU Siemann, Dietmar W.; Horsman, Michael R.
CS Department of Radiation Oncology, University of Florida Shands Cancer
Center, Gainesville, FL, 32610, USA
SO Current Opinion in Investigational Drugs (PharmaPress Ltd.) (2002), 3(11),
1660-1665
CODEN: COIDAZ; ISSN: 1472-4472
PB PharmaPress Ltd.
DT Journal; General Review
LA English
RE.CNT 56 THERE ARE 56 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 24 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:115478 CAPLUS
DN 139:223859
TI Anti-tumor and anti-vascular effects of the novel tubulin-binding agent
combretastatin A-1 phosphate
AU Holwell, S. E.; Cooper, P. A.; Thompson, M. J.; Pettit, G. R.; Lippert, J.
W., III; Martin, S. W.; Bibby, M. C.
CS Cancer Research Unit, University of Bradford, West Yorkshire, BD7 1DP, UK
SO Anticancer Research (2002), 22(6C), 3933-3940
CODEN: ANTRD4; ISSN: 0250-7005
PB International Institute of Anticancer Research
DT Journal
LA English
RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 25 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:102590 CAPLUS
DN 139:254840
TI Combretastatin A4 Phosphate Has Primary Antineoplastic Activity Against
Human Anaplastic Thyroid Carcinoma Cell Lines and Xenograft Tumors
AU Dziba, Joshua M.; Marcinek, Regina; Venkataraman, Gopalakrishnan;
Robinson, Jill A.; Ain, Kenneth B.
CS Thyroid Cancer Research Laboratory, Medical Service, Veterans Affairs
Medical Center, and the Dept. of Internal Medicine, University of Kentucky
Medical Center, Lexington, KY, USA
SO Thyroid (2002), 12(12), 1063-1070
CODEN: THYRER; ISSN: 1050-7256
PB Mary Ann Liebert, Inc.
DT Journal
LA English
RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 26 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:13579 CAPLUS
DN 139:254741
TI Marked potentiation of the antitumour activity of chemotherapeutic drugs
by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA)
AU Siim, Bronwyn G.; Lee, Alan E.; Shalal-Zwain, Sahar; Pruijn, Frederik B.;
Wilson, W. R.; Sim, B. G.; McKeage, M. J.
CS Auckland Cancer Society Research Centre, Experimental Oncology Group, The
University of Auckland, Auckland, N. Z.
SO Cancer Chemotherapy and Pharmacology (2003), 51(1), 43-52
CODEN: CCPHDZ; ISSN: 0344-5704
PB Springer-Verlag
DT Journal
LA English
RE.CNT 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 27 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2002:977780 CAPLUS
 DN 138:55802
 TI Preparation of combretastatin A3 diphosphate prodrugs for the treatment of cancer
 IN Pettit, George R.; Minardi, Mathew D.
 PA Arizona Board of Regents, USA
 SO PCT Int. Appl., 33 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002102766	A2	20021227	WO 2002-US19085	20020617
	WO 2002102766	A3	20030403		
	W: CA, JP, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
	EP 1395265	A2	20040310	EP 2002-746550	20020617
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
	US 2004029838	A1	20040212	US 2003-398543	20030407
PRAI	US 2001-298606P	P	20010615		
	WO 2002-US19085	W	20020617		

L3 ANSWER 28 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2002:896045 CAPLUS
 DN 139:374359
 TI Enhancement of vascular targeting by inhibitors of nitric oxide synthase
 AU Davis, Peter D.; Tozer, Gillian M.; Naylor, Matthew A.; Thomson, Peter; Lewis, Gemma; Hill, Sally A.
 CS Angiogene Pharmaceuticals Ltd., Oxford, OX4 4GA, UK
 SO International Journal of Radiation Oncology, Biology, Physics (2002), 54(5), 1532-1536
 CODEN: IOBPD3; ISSN: 0360-3016
 PB Elsevier Science Inc.
 DT Journal
 LA English

RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 29 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2002:896043 CAPLUS
 DN 139:347507
 TI Synergy between vascular targeting agents and antibody-directed therapy
 AU Pedley, R. Barbara; El-Emir, Ethaar; Flynn, Aiden A.; Boxer, Geoffrey M.; Dearling, Jason; Raleigh, James A.; Hill, Sally A.; Stuart, Sam; Motha, Reeya; Begent, Richard H. J.
 CS Cancer Research UK Targeting and Imaging Group, Department of Oncology, Royal Free and University College Medical School, London, NW3 2PF, UK
 SO International Journal of Radiation Oncology, Biology, Physics (2002), 54(5), 1524-1531
 CODEN: IOBPD3; ISSN: 0360-3016
 PB Elsevier Science Inc.
 DT Journal
 LA English

RE.CNT 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 30 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:896041 CAPLUS
DN 139:347506
TI Combination of vascular targeting agents with thermal or radiation therapy
AU Horsman, Michael R.; Murata, Rumi
CS Department of Experimental Clinical Oncology, Aarhus University Hospital,
Aarhus, DK-8000, Den.
SO International Journal of Radiation Oncology, Biology, Physics (2002),
54(5), 1518-1523
CODEN: IOBPD3; ISSN: 0360-3016
PB Elsevier Science Inc.
DT Journal
LA English
RE.CNT 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 31 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:896034 CAPLUS
DN 139:316714
TI The development of combretastatin A4 phosphate as a vascular targeting
agent
AU Chaplin, David J.; Hill, Sally A.
CS Oxigene Inc., Watertown, MA, 02472, USA
SO International Journal of Radiation Oncology, Biology, Physics (2002),
54(5), 1491-1496
CODEN: IOBPD3; ISSN: 0360-3016
PB Elsevier Science Inc.
DT Journal
LA English
RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 32 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:816161 CAPLUS
DN 138:378695
TI The vascular response of tumor and normal tissues on the rat to the
vascular targeting agent, combretastatin A-4-phosphate, at clinically
relevant doses
AU Prise, Vivien E.; Honess, Davina J.; Stratford, Michael R. L.; Wilson,
John; Tozer, Gillian M.
CS Tumor Microcirculation Group, Gray Cancer Institute, Mount Vernon
Hospital, Northwood, Middx, HA6 2JR, UK
SO International Journal of Oncology (2002), 21(4), 717-726
CODEN: IJONES; ISSN: 1019-6439
PB International Journal of Oncology
DT Journal
LA English
RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 33 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:799337 CAPLUS
DN 138:381528
TI Application of multiphoton steady state and lifetime imaging to mapping of
tumor vascular architecture in vivo
AU Ameer-Beg, Simon; Barber, Paul R.; Hodgkiss, R. J.; Locke, R. J.; Newman,
Robert G.; Tozer, Gillian M.; Vojnovic, Borivoj; Wilson, J.
CS Advanced Technology Dev. Group, Gray Cancer Inst., Northwood, Middlesex,
HA6 2JR, UK
SO Proceedings of SPIE-The International Society for Optical Engineering
(2002), 4620(Multiphoton Microscopy in the Biomedical Sciences II), 85-95
CODEN: PSISDG; ISSN: 0277-786X

PB SPIE-The International Society for Optical Engineering
 DT Journal
 LA English
 RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 34 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2002:794895 CAPLUS
 DN 138:297218
 TI Schedule dependence of combretastatin A4 phosphate in transplanted and
 spontaneous tumor models
 AU Hill, Sally A.; Chaplin, David J.; Lewis, Gemma; Tozer, Gillian M.
 CS Tumour Microcirculation Group, Gray Cancer Institute, Mount Vernon
 Hospital, Northwood, HA6 2JR, UK
 SO International Journal of Cancer (2002), 102(1), 70-74
 CODEN: IJCNAW; ISSN: 0020-7136
 PB Wiley-Liss, Inc.
 DT Journal
 LA English
 RE.CNT 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 35 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2002:755199 CAPLUS
 DN 137:284323
 TI Enzyme-cleavable prodrug compounds
 IN Dubois, Vincent; Fernandez, Anne Marie; Gangwar, Sanjeev; Lewis, Evan;
 Lobl, Thomas J.; Nieder, Matthew H.; Pickford, Lesley B.; Trouet, Andre;
 Yarranton, Geoffrey T.
 PA Belg.
 SO U.S. Pat. Appl. Publ., 86 pp., Cont.-in-part of Appl. No. PCT/US99/30393.
 CODEN: USXXCO
 DT Patent
 LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002142955	A1	20021003	US 2001-879442	20010611
	WO 2000033888	A2	20000615	WO 1999-US30393	19991210
	WO 2000033888	A3	20011108		
	W:				
	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,				
	CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,				
	IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD,				
	MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,				
	SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ,				
	BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,				
	DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,				
	CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 1998-111793P	P	19981211		
	US 1999-119312P	P	19990208		
	WO 1999-US30393	A2	19991210		
	US 2000-211887P	P	20000614		
	US 2001-290448P	P	20010511		
OS	MARPAT 137:284323				

L3 ANSWER 36 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2002:736049 CAPLUS
 DN 137:253007
 TI A combination comprising combretastatin and anticancer agents
 IN Bissery, Marie-Christine
 PA Aventis Pharma S.A., Fr.

SO PCT Int. Appl., 19 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002074229	A2	20020926	WO 2002-EP3322	20020315
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 2002183266	A1	20021205	US 2002-92508	20020308
	US 2003060429	A1	20030327	US 2002-97926	20020315
	WO 2004037258	A1	20040506	WO 2002-EP6758	20020315
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	NO 2003004022	A	20030911	NO 2003-4022	20030911
PRAI	US 2001-275627P	P	20010315		
	WO 2002-EP6758	W	20020315		

L3 ANSWER 37 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2002:651667 CAPLUS

DN 138:214971

TI Preclinical evaluation of the antitumor activity of the novel vascular-targeting agent Oxi 4503

AU Hill, Sally A.; Tozer, Gillian M.; Pettit, George R.; Chaplin, David J.
CS Gray Cancer Institute, Mount Vernon Hospital, Northwood, Middlesex, HA6 2JR, UK

SO Anticancer Research (2002), 22(3), 1453-1458

CODEN: ANTRD4; ISSN: 0250-7005

PB International Institute of Anticancer Research

DT Journal

LA English

RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 38 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2002:555278 CAPLUS

DN 137:119643

TI Methods using a combretastatin compound combined with an antitumor agent for modulating tumor growth and metastasis

IN Lee, Francis Y.; Peck, Ronald; Chaplin, David; Pero, Ronald; Edvardsen, Klaus

PA Bristol-Myers Squibb Company, USA; Oxigene, Inc.

SO PCT Int. Appl., 69 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002056692	A1	20020725	WO 2001-US50261	20011220
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	EP 1351573	A1	20031015	EP 2001-994435	20011220
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
PRAI	US 2000-258195P	P	20001222		
	WO 2001-US50261	W	20011220		
RE.CNT	3	THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT			

L3 ANSWER 39 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:471932 CAPLUS
DN 137:163285
TI A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin A-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer
AU Dowlati, Afshin; Robertson, Kelly; Cooney, Matthew; Petros, William P.; Stratford, Michael; Jesberger, John; Rafie, Niuscha; Overmoyer, Beth; Makkar, Vinit; Stambler, Bruce; Taylor, Anne; Waas, John; Lewin, Jonathan S.; McCrae, Keith R.; Remick, Scot C.
CS Division of Hematology/Oncology, Department of Medicine, School of Medicine, Case Western Reserve University (CWRU), Cleveland, OH, 44106, USA
SO Cancer Research (2002), 62(12), 3408-3416
CODEN: CNREA8; ISSN: 0008-5472
PB American Association for Cancer Research
DT Journal
LA English
RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 40 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:455498 CAPLUS
DN 138:52015
TI Acute effects of vascular modifying agents in solid tumors assessed by noninvasive laser doppler flowmetry and near infrared spectroscopy
AU Kragh, Michael; Quistorff, Bjorn; Horsman, Michael R.; Kristjansen, Paul E. G.
CS Institute of Molecular Pathology, Panum Institute, University of Copenhagen, Copenhagen, DK-2200, Den.
SO Neoplasia (New York, NY, United States) (2002), 4(3), 263-267
CODEN: NEOPFL; ISSN: 1522-8002
PB Nature Publishing Group
DT Journal
LA English
RE.CNT 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 41 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:419476 CAPLUS
DN 138:32901

TI Combretastatin A-1 phosphate a novel tubulin-binding agent with in vivo
anti vascular effects in experimental tumours
AU Holwell, S. E.; Cooper, P. A.; Grosios, K.; Lippert, J. W., III; Pettit,
G. R.; Shnyder, S. D.; Bibby, M. C.
CS Cancer Research Unit, University of Bradford, Bradford, BD7 1DP, UK
SO Anticancer Research (2002), 22(2A), 707-711
CODEN: ANTRD4; ISSN: 0250-7005
PB International Institute of Anticancer Research
DT Journal
LA English
RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 42 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:284300 CAPLUS
DN 137:149895
TI Vascular targeting agents enhance chemotherapeutic agent activities in
solid tumor therapy
AU Siemann, Dietmar W.; Mercer, Emma; Lepler, Sharon; Rojiani, Aryn M.
CS Department of Radiation Oncology, Shands Cancer Center, University of
Florida, Gainesville, FL, 32610, USA
SO International Journal of Cancer (2002), 99(1), 1-6
CODEN: IJCNAW; ISSN: 0020-7136
PB Wiley-Liss, Inc.
DT Journal
LA English
RE.CNT 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 43 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:257650 CAPLUS
DN 137:241782
TI Differential sensitivity of two adenocarcinoma xenografts to the
anti-vascular drugs combretastatin A4 phosphate and 5,6-dimethylxanthenone-
4-acetic acid, assessed using MRI and MRS
AU Beauregard, Daniel A.; Pedley, R. Barbara; Hill, Sally A.; Brindle, Kevin
M.
CS Department of Biochemistry, University of Cambridge, Cambridge, CB2 1GA,
UK
SO NMR in Biomedicine (2002), 15(2), 99-105
CODEN: NMRBEF; ISSN: 0952-3480
PB John Wiley & Sons Ltd.
DT Journal
LA English
RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 44 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:257649 CAPLUS
DN 137:241613
TI Evaluation of the anti-vascular effects of combretastatin in rodent
tumours by dynamic contrast enhanced MRI
AU Maxwell, Ross J.; Wilson, John; Prise, Vivien E.; Vojnovic, Borivoj;
Rustin, Gordon J.; Lodge, Martin A.; Tozer, Gillian M.
CS Mount Vernon Hospital, Gray Cancer Institute, Northwood, Middlesex, HA6
2JR, UK
SO NMR in Biomedicine (2002), 15(2), 89-98
CODEN: NMRBEF; ISSN: 0952-3480
PB John Wiley & Sons Ltd.
DT Journal
LA English
RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 45 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2002:220602 CAPLUS
 DN 136:268115
 TI Combretastatin A-4 phosphate prodrug mono- and di-organic amine salts,
 mono- and di- amino acid salts, and mono- and di-amino acid ester salts
 IN Venit, John J.; Dali, Mandar V.; Dali, Manisha M.; Huang, Yande; Dahlheim,
 Charles E.; Tejwani, Ravindra W.
 PA Bristol-Myers Squibb Company, USA
 SO PCT Int. Appl., 84 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002022626	A1	20020321	WO 2001-US28401	20010912
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				
	GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,				
	LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL,				
	PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,				
	US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,				
	DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,				
	BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2002072507	A1	20020613	US 2001-950500	20010911
	US 6670344	B2	20031230		
	AU 2001090771	A5	20020326	AU 2001-90771	20010912
	BR 2001007210	A	20030225	BR 2001-7210	20010912
	EE 200200249	A	20030616	EE 2002-249	20010912
	EP 1320534	A1	20030625	EP 2001-970806	20010912
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
	IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004509128	T2	20040325	JP 2002-526877	20010912
	NO 2002002270	A	20020701	NO 2002-2270	20020513
	US 2004054212	A1	20040318	US 2003-660439	20030910
PRAI	US 2000-232568P	P	20000914		
	US 2000-251921P	P	20001207		
	US 2001-950500	A1	20010911		
	WO 2001-US28401	W	20010912		

OS MARPAT 136:268115

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 46 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2002:219473 CAPLUS
 DN 137:119212
 TI The tumor vascular targeting agent combretastatin A-4-phosphate induces
 reorganization of the actin cytoskeleton and early membrane blebbing in
 human endothelial cells
 AU Kanthou, Chryso; Tozer, Gillian M.
 CS Tumour Microcirculation Group, Gray Cancer Institute, Middlesex, HA6 2JR,
 UK
 SO Blood (2002), 99(6), 2060-2069
 CODEN: BLOOAW; ISSN: 0006-4971
 PB American Society of Hematology
 DT Journal
 LA English
 RE.CNT 67 THERE ARE 67 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 47 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2002:180157 CAPLUS
 DN 138:55697
 TI Synthesis of disodium combretastatin A-4 3'-O-phosphate
 AU Zhao, Huiping; Chen, Guorong; Li, Yuanchao
 CS Department of Fine Chemistry, East China University of Science +
 Technology, Shanghai, 200237, Peop. Rep. China
 SO Zhongguo Yiyao Gongye Zazhi (2001), 32(12), 531-532, 535
 CODEN: ZYGZEA; ISSN: 1001-8255
 PB Zhongguo Yiyao Gongye Zazhi Bianjibu
 DT Journal
 LA Chinese
 OS CASREACT 138:55697

L3 ANSWER 48 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2002:157495 CAPLUS
 DN 136:205412
 TI Oligopeptide-based prodrugs activated by plasmin and their use in cancer
 chemotherapy
 IN Trouet, Andre; Dubois, Vincent; Passioukov, Alexandre
 PA Coulter Pharmaceutical, Inc., USA
 SO PCT Int. Appl., 67 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002015700	A1	20020228	WO 2001-US26476	20010823
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				
	GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,				
	LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,				
	RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US,				
	UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,				
	DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,				
	BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2001086727	A5	20020304	AU 2001-86727	20010823
PRAI	US 2000-227686P	P	20000824		
	WO 2001-US26476	W	20010823		

OS MARPAT 136:205412

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 49 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2002:151298 CAPLUS
 DN 137:288554
 TI The influence of combretastatin A-4 and vinblastine on interstitial fluid
 pressure in BT4An rat gliomas
 AU Eikesdal, Hans Petter; Landuyt, Willy; Dahl, Olav
 CS Department of Oncology, University of Bergen, Haukeland University
 Hospital, Bergen, 5021, Norway
 SO Cancer Letters (Shannon, Ireland) (2002), 178(2), 209-217
 CODEN: CALEDQ; ISSN: 0304-3835
 PB Elsevier Science Ireland Ltd.
 DT Journal
 LA English
 RE.CNT 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 50 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2002:142717 CAPLUS
 DN 136:183937
 TI Preparation and use of cis-stilbene derivatives with vascular damaging activity
 IN Davis, Peter David
 PA Angiogene Pharmaceuticals Ltd., UK
 SO PCT Int. Appl., 21 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 2002014329	A1	20020221	WO 2001-GB3668	20010815	
	W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
	RW:			GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG		
	AU 2001077629	A5	20020225	AU 2001-77629	20010815	
	EP 1311514	A1	20030521	EP 2001-955467	20010815	
	R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR		
	US 2003181424	A1	20030925	US 2003-367606	20030214	
PRAI	GB 2000-19944	A	20000815			
	WO 2001-GB3668	W	20010815			
OS	MARPAT 136:183937					
RE.CNT 7	THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT					

L3 ANSWER 51 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2002:72094 CAPLUS
 DN 136:134622
 TI Methods of synthesizing prodrugs of combretastatin A-4
 IN Seyedi, Faye; Gale, Jonathan; Haider, Reem; Hoare, John
 PA Oxigene, Inc., USA
 SO PCT Int. Appl., 41 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 2002006279	A1	20020124	WO 2001-US22403	20010717	
	WO 2002006279	C1	20020418			
	WO 2002006279	C2	20030403			
	W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
	RW:			GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG		
	US 2002119951	A1	20020829	US 2001-908321	20010717	
PRAI	US 2000-218766P	P	20000717			

OS CASREACT 136:134622

L3 ANSWER 52 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2002:10314 CAPLUS

DN 136:86054

TI Tripeptide prodrug compounds

IN Bebbington, Christopher R.; Dubois, Vincent; Gangwar, Sanjeev; Lobl, Thomas J.; Nieder, Matthew H.; Pickford, Leslie B.; Trouet, Andre; Yarranton, Geoffrey T.

PA Corixa Corporation, USA

SO PCT Int. Appl., 102 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002000263	A2	20020103	WO 2001-US40925	20010611
	WO 2002000263	A3	20020815		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1294403	A2	20030326	EP 2001-942249	20010611
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004501875	T2	20040122	JP 2002-505044	20010611
	US 2003181359	A1	20030925	US 2002-311519	20021213
PRAI	US 2000-212880P	P	20000614		
	WO 2001-US40925	W	20010611		
OS	CASREACT 136:86054; MARPAT 136:86054				

L3 ANSWER 53 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2001:923644 CAPLUS

DN 136:58787

TI Enzyme-cleavable prodrug compounds

IN Nieder, Matthew H.; Dubois, Vincent; Gangwar, Sanjeev; Lobl, Thomas J.; Pickford, Leslie B.; Trouet, Andre; Yarranton, Geoffrey T.

PA Corixa Corporation, USA

SO PCT Int. Appl., 159 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001095945	A2	20011220	WO 2001-US18903	20010611
	WO 2001095945	A3	20020815		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

EP 1294405 A2 20030326 EP 2001-950291 20010611
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 JP 2004510703 T2 20040408 JP 2002-510122 20010611
 PRAI US 2000-211887P P 20000614
 US 2001-290448P P 20010511
 WO 2001-US18903 W 20010611
 OS MARPAT 136:58787

L3 ANSWER 54 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2001:923642 CAPLUS
 DN 136:74618
 TI Prodrug compounds with isoleucine
 IN Pickford, Lesley B.; Gangwar, Sanjeev; Lobl, Thomas J.; Nieder, Matthew
 H.; Yarranton, Geoffrey T.
 PA Corixa Corporation, USA
 SO PCT Int. Appl., 107 pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001095943	A2	20011220	WO 2001-US18857	20010611
	WO 2001095943	A3	20020829		
	W:		AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
	RW:		GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG		
	EP 1294404	A2	20030326	EP 2001-944442	20010611
	R:		AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR		
	JP 2004510702	T2	20040408	JP 2002-510120	20010611
	US 2004039160	A1	20040226	US 2002-311411	20021213
PRAI	US 2000-211686P	P	20000614		
	WO 2001-US18857	W	20010611		
OS	MARPAT 136:74618				

L3 ANSWER 55 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2001:864436 CAPLUS
 DN 137:119128
 TI Tumor vasculature is targeted by the combination of combretastatin A-4 and
 hyperthermia
 AU Eikesdal, Hans Peter; Bjerkvig, Rolf; Raleigh, James A.; Mella, Olav;
 Dahl, Olav
 CS Department of Oncology, University of Bergen, Haukeland University
 Hospital, Bergen, 5021, Norway
 SO Radiotherapy and Oncology (2001), 61(3), 313-320
 CODEN: RAONDT; ISSN: 0167-8140
 PB Elsevier Science Ireland Ltd.
 DT Journal
 LA English
 RE.CNT 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 56 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2001:853282 CAPLUS

DN 136:241225
 TI Study of the anticancer effects of the vascular targeting agent
 combretastatin A-4 disodium phosphate
 AU Li, Lingyun
 CS Univ. of Florida, Gainesville, FL, USA
 SO (2000) 127 pp. Avail.: UMI, Order No. DA9997827
 From: Diss. Abstr. Int., B 2001, 61(12), 6410
 DT Dissertation
 LA English

L3 ANSWER 57 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2001:811045 CAPLUS
 DN 137:43550
 TI Combretastatin A-4 disodium phosphate: a vascular targeting agent that
 improves the anti-tumor effects of hyperthermia, radiation, and mild
 thermoradiotherapy
 AU Murata, Rumi; Overgaard, Jens; Horsman, Michael R.
 CS Department of Experimental Clinical Oncology, Aarhus University Hospital,
 Danish Cancer Society, Aarhus, Den.
 SO International Journal of Radiation Oncology, Biology, Physics (2001),
 51(4), 1018-1024
 CODEN: IOBPD3; ISSN: 0360-3016
 PB Elsevier Science Inc.
 DT Journal
 LA English

RE.CNT 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 58 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2001:798232 CAPLUS
 DN 135:344595
 TI Preparation of combretastatin A-1 phosphate and combretastatin B-1
 phosphate prodrugs with increased solubility
 IN Pettit, George R.; Lippert, John W., III
 PA Arizona Board of Regents, A Body Corporate of the State of Arizona, Acting
 for and On Behalf of Arizona State University, USA
 SO PCT Int. Appl., 41 pp.
 CODEN: PIXXD2
 DT Patent
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001081355	A1	20011101	WO 2001-US13858	20010427
	W: CA, JP, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,				
	PT, SE, TR				
	EP 1278758	A1	20030129	EP 2001-928978	20010427
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
	IE, FI, CY, TR				
	US 2003220298	A1	20031127	US 2002-258672	20021025
PRAI	US 2000-200395P	P	20000427		
	WO 2001-US13858	W	20010427		
OS	CASREACT 135:344595				

RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 59 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2001:798176 CAPLUS
 DN 135:331299
 TI Synthesis of hydroxyphenstatin and the prodrugs thereof as anticancer and
 antimicrobial agents

IN Pettit, George R.; Grealish, Matthew P.
PA Arizona Board of Regents, A Body Corporate of the State of Arizona, Acting
for and On Behalf of Arizona State University, USA
SO PCT Int. Appl., 40 pp.
CODEN: PIXXD2

DT Patent
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001081288	A1	20011101	WO 2001-US13731	20010427
	W: CA, JP, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,				
	PT, SE, TR				
	EP 1299337	A1	20030409	EP 2001-930892	20010427
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
	IE, FI, CY, TR				
	US 2003220304	A1	20031127	US 2003-258676	20030424
PRAI	US 2000-200394P	P	20000427		
	WO 2001-US13731	W	20010427		

OS MARPAT 135:331299

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 60 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:712132 CAPLUS
DN 136:79365
TI The susceptibility of tumors to the antivasular drug combretastatin A4
phosphate correlates with vascular permeability
AU Beauregard, Daniel A.; Hill, Sally A.; Chaplin, Dai J.; Brindle, Kevin M.
CS Department of Biochemistry, University of Cambridge, Cambridge, CB2 1GA,
UK
SO Cancer Research (2001), 61(18), 6811-6815
CODEN: CNREA8; ISSN: 0008-5472
PB American Association for Cancer Research
DT Journal
LA English
RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 61 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:659027 CAPLUS
DN 136:295
TI Mechanisms associated with tumor vascular shut-down induced by
combretastatin A-4 phosphate: intravital microscopy and measurement of
vascular permeability
AU Tozer, Gillian M.; Prise, Vivien E.; Wilson, John; Cemazar, Maja; Shan,
Siqing; Dewhirst, Mark W.; Barber, Paul R.; Vojnovic, Borivoj; Chaplin,
David J.
CS Gray Cancer Institute, Mount Vernon Hospital, Northwood, HA6 2JR, UK
SO Cancer Research (2001), 61(17), 6413-6422
CODEN: CNREA8; ISSN: 0008-5472
PB American Association for Cancer Research
DT Journal
LA English
RE.CNT 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 62 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:612313 CAPLUS
DN 136:31380
TI Antineoplastic agents 463. Synthesis of combretastatin A-3 diphosphate

prodrugs
AU Pettit, George R.; Minardi, Mathew D.; Boyd, Michael R.; Pettit, Robin K.
CS Cancer Research Institute and Department of Chemistry and Biochemistry,
Arizona State University, Tempe, AZ, 85287-2404, USA
SO Anti-Cancer Drug Design (2001), Volume Date 2000, 15(6), 397-403
CODEN: ACDDEA; ISSN: 0266-9536
PB Oxford University Press
DT Journal
LA English
RE.CNT 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 63 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:483534 CAPLUS
DN 136:318886
TI Interaction between combretastatin A-4 disodium phosphate and radiation in
murine tumors
AU Murata, R.; Siemann, D. W.; Overgaard, J.; Horsman, M. R.
CS Danish Cancer Society, Department of Experimental Clinical Oncology,
Aarhus University Hospital, Aarhus, DK-8000, Den.
SO Radiotherapy and Oncology (2001), 60(2), 155-161
CODEN: RAONDT; ISSN: 0167-8140
PB Elsevier Science Ireland Ltd.
DT Journal
LA English
RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 64 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:465870 CAPLUS
DN 135:238667
TI Eradication of colorectal xenografts by combined radioimmunotherapy and
combretastatin A-4 3-O-phosphate
AU Pedley, R. Barbara; Hill, Sally A.; Boxer, Geoffrey M.; Flynn, Aiden A.;
Boden, Robert; Watson, Rebecca; Dearling, Jason; Chaplin, David J.;
Begent, Richard H. J.
CS Department of Oncology, Royal Free and University College Medical School,
London, NW3 2PF, UK
SO Cancer Research (2001), 61(12), 4716-4722
CODEN: CNREA8; ISSN: 0008-5472
PB American Association for Cancer Research
DT Journal
LA English
RE.CNT 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 65 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:379423 CAPLUS
DN 135:189977
TI Specific targeting of cytosine deaminase to solid tumors by engineered
Clostridium acetobutylicum
AU Theys, Jan; Landuyt, Willy; Nuyts, Sandra; Van Mellaert, Lieve; Van
Oosterom, Allan; Lambin, Philippe; Anne, Jozef
CS Laboratory of Bacteriology, Rega Institute for Medical Research, Louvain,
B-3000, Belg.
SO Cancer Gene Therapy (2001), 8(4), 294-297
CODEN: CGTHEG; ISSN: 0929-1903
PB Nature America Inc.
DT Journal
LA English
RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 66 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:294493 CAPLUS
DN 135:220760
TI Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumor vascular targeting activity in vivo
AU Galbraith, Susan M.; Chaplin, David J.; Lee, Francesca; Stratford, Michael R. L.; Locke, Rosalind J.; Vojnovic, Borivoj; Tozer, Gillian M.
CS Tumour Microcirculation Group, Gray Laboratory Cancer Research Trust, Northwood, HA6 2JR, UK
SO Anticancer Research (2001), 21(1A), 93-102
CODEN: ANTRD4; ISSN: 0250-7005
PB International Institute of Anticancer Research
DT Journal
LA English
RE.CNT 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 67 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:285856 CAPLUS
DN 135:251511
TI Combretastatin-A4 disrupts neovascular development in non-neoplastic tissue
AU Griggs, J.; Hesketh, R.; Smith, G. A.; Brindle, K. M.; Metcalfe, J. C.; Thomas, G. A.; Williams, E. D.
CS Department of Biochemistry, University of Cambridge, Cambridge, CB2 1QW, UK
SO British Journal of Cancer (2001), 84(6), 832-835
CODEN: BJCAAI; ISSN: 0007-0920
PB Harcourt Publishers Ltd.
DT Journal
LA English
RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 68 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:175425 CAPLUS
DN 134:348060
TI Comparative effects of combretastatin A-4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on blood perfusion in a murine tumour and normal tissues
AU Murata, R.; Overgaard, J.; Horsman, M. R.
CS Danish Cancer Society, Department of Experimental Clinical Oncology, Aarhus University Hospital, Aarhus, DK-8000, Den.
SO International Journal of Radiation Biology (2001), 77(2), 195-204
CODEN: IJRBE7; ISSN: 0955-3002
PB Taylor & Francis Ltd.
DT Journal
LA English
RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 69 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:125583 CAPLUS
DN 134:348034
TI Evaluation of combretastatin A-4 prodrug in a non-Hodgkin's lymphoma xenograft model: preclinical efficacy
AU Nabha, Sanaa M.; Mohammad, Ramzi M.; Wall, Nathan R.; Dutcher, Julie A.; Salkini, Bashar M.; Pettit, George R.; Al-Katib, Ayad M.
CS Division of Hematology and Oncology, Department of Internal Medicine, School of Medicine, Wayne State University, Detroit, MI, 48201, USA
SO Anti-Cancer Drugs (2001), 12(1), 57-63

CODEN: ANTDEV; ISSN: 0959-4973

PB Lippincott Williams & Wilkins

DT Journal

LA English

RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 70 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2001:113357 CAPLUS

DN 135:189844

TI In vivo antitumor effect of vascular targeting combined with either
ionizing radiation or anti-angiogenesis treatment

AU Landuyt, W.; Ahmed, B.; Nuyts, S.; Theys, J.; Op de Beeck, M.; Rijnders,
A.; Anne, J.; van Oosterom, A.; Van den Bogaert, W.; Lambin, P.

CS Laboratory of Experimental Radiobiology, Katholieke Universiteit, Louvain,
Belg.

SO International Journal of Radiation Oncology, Biology, Physics (2001),
49(2), 443-450

CODEN: IOBPD3; ISSN: 0360-3016

PB Elsevier Science Inc.

DT Journal

LA English

RE.CNT 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 71 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2001:113153 CAPLUS

DN 134:320618

TI Improvement of Clostridium tumor targeting vectors evaluated in rat
rhabdomyosarcomas

AU Theys, J.; Landuyt, W.; Nuyts, S.; Van Mellaert, L.; Bosmans, E.;
Rijnders, A.; Van Den Bogaert, W.; van Oosterom, A.; Anne, J.; Lambin, P.

CS Laboratory of Bacteriology, Rega Institute for Medical Research, K.U.
Leuven, Louvain, B-3000, Belg.

SO FEMS Immunology and Medical Microbiology (2001), 30(1), 37-41

CODEN: FIMIEV; ISSN: 0928-8244

PB Elsevier Science B.V.

DT Journal

LA English

RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 72 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2001:35285 CAPLUS

DN 135:70797

TI Combretastatin A-4 and doxorubicin combination treatment is effective in a
preclinical model of human medullary thyroid carcinoma

AU Nelkin, Barry D.; Ball, Douglas W.

CS Department of Oncology, Johns Hopkins University School of Medicine,
Baltimore, MD, 21231, USA

SO Oncology Reports (2001), 8(1), 157-160

CODEN: OCRPEW; ISSN: 1021-335X

PB Oncology Reports

DT Journal

LA English

RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 73 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2000:757705 CAPLUS

DN 134:51116

TI Antineoplastic agents 429. Syntheses of the combretastatin A-1 and

combretastatin B-1 prodrugs
 AU Pettit, George R.; Lippert, John W., III
 CS Cancer Research Institute and Department of Chemistry and Biochemistry,
 Arizona State University, Tempe, AZ, 85287-2404, USA
 SO Anti-Cancer Drug Design (2000), 15(3), 203-216
 CODEN: ACDDEA; ISSN: 0266-9536
 PB Oxford University Press
 DT Journal
 LA English
 RE.CNT 94 THERE ARE 94 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 74 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2000:717223 CAPLUS
 DN 134:216909
 TI Determinants of anti-vascular action by combretastatin A-4 phosphate: role
 of nitric oxide
 AU Parkins, C. S.; Holder, A. L.; Hill, S. A.; Chaplin, D. J.; Tozer, G. M.
 CS Tumour Microcirculation Group, Gray Laboratory Cancer Research Trust,
 Mount Vernon Hospital, Northwood, HA6 2JR, UK
 SO British Journal of Cancer (2000), 83(6), 811-816
 CODEN: BJCAAI; ISSN: 0007-0920
 PB Harcourt Publishers Ltd.
 DT Journal
 LA English
 RE.CNT 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 75 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2000:619056 CAPLUS
 DN 134:246933
 TI Vascular targeting of solid tumors: a major 'inverse' volume-response
 relationship following combretastatin A-4 phosphate treatment of rat
 rhabdomyosarcomas
 AU Landuyt, W.; Verdoes, O.; Darius, D. O.; Drijconingen, M.; Nuyts, S.;
 Theys, J.; Stockx, L.; Wynendaele, W.; Fowler, J. F.; Maleux, G.; Van den
 Bogaert, W.; Anne, J.; van Oosterom, A.; Lambin, P.
 CS Department of Experimental Radiobiology/Radiotherapy, Catholic University
 of Leuven (KULeuven), University Hospital Gasthuisberg, Louvain, B-3000,
 Belg.
 SO European Journal of Cancer (2000), 36(14), 1833-1843
 CODEN: EJCAEL; ISSN: 0959-8049
 PB Elsevier Science Ltd.
 DT Journal
 LA English
 RE.CNT 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 76 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2000:592560 CAPLUS
 DN 133:198575
 TI Compositions and methods for use in targeting vascular destruction
 IN Pero, Ronald W.; Sherris, David
 PA Oxigene, Inc., USA
 SO PCT Int. Appl., 36 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	----	-----	-----
PI	WO 2000048606	A1	20000824	WO 2000-US3996	20000216

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2358925 AA 20000824 CA 2000-2358925 20000216
 EP 1152764 A1 20011114 EP 2000-914606 20000216
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

JP 2002537262 T2 20021105 JP 2000-599398 20000216
 US 6538038 B1 20030325 US 2000-505402 20000216
 US 2003109500 A1 20030612 US 2002-218833 20020814

PRAI US 1999-120478P P 19990218
 US 2000-505402 A1 20000216
 WO 2000-US3996 W 20000216

OS MARPAT 133:198575

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 77 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2000:592549 CAPLUS
 DN 133:172166
 TI Combinations for the treatment of diseases involving angiogenesis
 IN Davis, Peter David
 PA Angiogene Pharmaceuticals Ltd., UK
 SO PCT Int. Appl., 18 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000048591	A1	20000824	WO 2000-GB511	20000215
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
BR 2000008254	A	20011106	BR 2000-8254	20000215
EP 1161235	A1	20011212	EP 2000-903832	20000215
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002537251	T2	20021105	JP 2000-599383	20000215
NZ 513429	A	20031031	NZ 2000-513429	20000215
ZA 2001006688	A	20020814	ZA 2001-6688	20010814
NO 2001003966	A	20011015	NO 2001-3966	20010815
PRAI GB 1999-3404	A	19990216		
WO 2000-GB511	W	20000215		

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 78 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2000:443011 CAPLUS
 DN 133:207722

TI Antineoplastic Agents 440. Asymmetric Synthesis and Evaluation of the Combretastatin A-1 SAR Probes (1S,2S)- and (1R,2R)-1,2-Dihydroxy-1-(2',3'-dihydroxy-4'-methoxyphenyl)-2-(3'',4'',5''-trimethoxyphenyl)-ethane

AU Pettit, George R.; Lippert, John W., III; Herald, Delbert L.; Hamel, Ernest; Pettit, Robin K.

CS Cancer Research Institute and Department of Chemistry, Arizona State University, Tempe, AZ, 85287-2404, USA

SO Journal of Natural Products (2000), 63(7), 969-974
CODEN: JNPRDF; ISSN: 0163-3864

PB American Chemical Society

DT Journal

LA English

RE.CNT 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 79 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2000:425859 CAPLUS

DN 133:207717

TI Antineoplastic Agents. 443. Synthesis of the Cancer Cell Growth Inhibitor Hydroxyphenstatin and Its Sodium Diphosphate Prodrug

AU Pettit, George R.; Grealish, Matthew P.; Herald, Delbert L.; Boyd, Michael R.; Hamel, Ernest; Pettit, Robin K.

CS Cancer Research Institute and Department of Chemistry and Biochemistry, Arizona State University, Tempe, AZ, 85287-2404, USA

SO Journal of Medicinal Chemistry (2000), 43(14), 2731-2737
CODEN: JMCMAR; ISSN: 0022-2623

PB American Chemical Society

DT Journal

LA English

RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 80 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2000:401690 CAPLUS

DN 133:48878

TI Oligopeptide prodrug compounds and process for preparation thereof

IN Lobl, Thomas J.; Dubois, Vincent; Fernandez, Anne-Marie; Gangwar, Sanjeev; Lewis, Evan; Nieder, Matthew H.; Trouet, Andre; Viski, Peter; Yarranton, Geoffrey T.

PA Coulter Pharmaceutical, Inc., USA

SO PCT Int. Appl., 125 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000033888	A2	20000615	WO 1999-US30393	19991210
	WO 2000033888	A3	20011108		
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	EP 1144011	A2	20011017	EP 1999-967462	19991210
	EP 1144011	A3	20020206		
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,			

IE, SI, LT, LV, FI, RO
 JP 2003518000 T2 20030603 JP 2000-586378 19991210
 US 2002142955 A1 20021003 US 2001-879442 20010611
 PRAI US 1998-111793P P 19981211
 US 1999-119312P P 19990208
 WO 1999-US30393 W 19991210
 US 2000-211887P P 20000614
 US 2001-290448P P 20010511
 OS MARPAT 133:48878

L3 ANSWER 81 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2000:279432 CAPLUS
 DN 133:171912
 TI Combination chemotherapy with combretastatin A-4 phosphate and
 5-fluorouracil in an experimental murine colon adenocarcinoma
 AU Grosios, K.; Loadman, P. M.; Swaine, D. J.; Pettit, G. R.; Bibby, M. C.
 CS Clinical Oncology Unit, University of Bradford, Bradford, BD71DP, UK
 SO Anticancer Research (2000), 20(1A), 229-233
 CODEN: ANTRD4; ISSN: 0250-7005
 PB International Institute of Anticancer Research
 DT Journal
 LA English
 RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 82 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2000:56669 CAPLUS
 DN 132:303079
 TI In vivo and in vitro evaluation of combretastatin A-4 and its sodium
 phosphate prodrug
 AU Grosios, K.; Holwell, S. E.; McGown, A. T.; Pettit, G. R.; Bibby, M. C.
 CS Clinical Oncology Unit, University of Bradford, Bradford, BD7 1DP, UK
 SO British Journal of Cancer (1999), 81(8), 1318-1327
 CODEN: BJCAAI; ISSN: 0007-0920
 PB Churchill Livingstone
 DT Journal
 LA English
 RE.CNT 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 83 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1999:451301 CAPLUS
 DN 131:73507
 TI Preparation and formulation of combretastatin A4 prodrugs and their
 trans-isomers for use as antitumor agents
 IN Pettit, George R.; Rhodes, Monte R.
 PA Arizona State University, USA
 SO PCT Int. Appl., 55 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9935150	A1	19990715	WO 1999-US419	19990108
W: CA, JP, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2314238	AA	19990715	CA 1999-2314238	19990108
EP 1045853	A1	20001025	EP 1999-902121	19990108
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
JP 2002500227	T2	20020108	JP 2000-527548	19990108

PRAI US 1998-71070P P 19980109
 US 1998-111531P P 19981209
 WO 1999-US419 W 19990108
 RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 84 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1999:451177 CAPLUS
 DN 131:73506
 TI Synthesis and formulation of phenstatin and related prodrugs for use as
 antitumor agents
 IN Pettit, George R.; Toki, Brian
 PA Arizona State University, USA
 SO PCT Int. Appl., 39 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9934788	A1	19990715	WO 1999-US475	19990109
	W: CA, JP, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2314510	AA	19990715	CA 1999-2314510	19990109
	EP 1045689	A1	20001025	EP 1999-902133	19990109
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
	JP 2002500184	T2	20020108	JP 2000-527239	19990109
PRAI	US 1998-70878P	P	19980109		
	WO 1999-US475	W	19990109		
OS	MARPAT 131:73506				
RE.CNT	3				
	THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT				

L3 ANSWER 85 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1999:298062 CAPLUS
 DN 131:111003
 TI Anti-vascular approaches to solid tumor therapy: evaluation of
 combretastatin A4 phosphate
 AU Chaplin, D. J.; Pettit, G. R.; Hill, S. A.
 CS Tumour Microcirculation Group, Gray Laboratory Cancer Research Trust,
 Mount Vernon Hospital, Northwood, Middlesex, UK
 SO Anticancer Research (1999), 19(1A), 189-196
 CODEN: ANTRD4; ISSN: 0250-7005
 PB International Institute of Anticancer Research
 DT Journal
 LA English
 RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 86 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1999:284035 CAPLUS
 DN 131:82669
 TI Antineoplastic agents 393. Synthesis of the trans-isomer of combretastatin
 A-4 prodrug
 AU Pettit, George R.; Rhodes, Monte R.; Herald, Delbert L.; Chaplin, Dai J.;
 Stratford, Michael R. L.; Hamel, Ernest; Pettit, Robin K.; Chapuis,
 Jean-Charles; Oliva, Deanna
 CS Cancer Research Institute and Department of Chemistry, Arizona State
 University, Tempe, AZ, 85287-2494, USA
 SO Anti-Cancer Drug Design (1998), 13(8), 981-993
 CODEN: ACDDEA; ISSN: 0266-9536

PB Oxford University Press
DT Journal
LA English

RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 87 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1999:241795 CAPLUS
DN 131:39356
TI Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues
AU Tozer, Gillian M.; Prise, Vivien E.; Wilson, John; Locke, Rosalind J.; Vojnovic, Borivoj; Stratford, Michael R. L.; Dennis, Madeleine F.; Chaplin, David J.
CS Tumor Microcirculation Group, Gray Laboratory Cancer Research Trust, Mount Vernon Hospital, Northwood, HA6 2JR, UK
SO Cancer Research (1999), 59(7), 1626-1634
CODEN: CNREA8; ISSN: 0008-5472
PB AACR Subscription Office
DT Journal
LA English
RE.CNT 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 88 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1999:222768 CAPLUS
DN 131:31823
TI Antineoplastic Agents. 410. Asymmetric Hydroxylation of trans-Combretastatin A-4
AU Pettit, George R.; Toki, Brian E.; Herald, Delbert L.; Boyd, Michael R.; Hamel, Ernest; Pettit, Robin K.; Chapuis, J. Charles
CS Cancer Research Institute and Department of Chemistry, Arizona State University, Tempe, AZ, 85287-2404, USA
SO Journal of Medicinal Chemistry (1999), 42(8), 1459-1465
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
OS CASREACT 131:31823
RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 89 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1999:89966 CAPLUS
DN 130:261394
TI Determination of combretastatin A-4 and its drug in plasma by high-performance liquid chromatography
AU Stratford, Michael R. L.; Dennis, Madeleine F.
CS Gray Laboratory Cancer Research Trust, Mount Vernon Hospital, Northwood/Middlesex, HA6 2JR, UK
SO Journal of Chromatography, B: Biomedical Sciences and Applications (1999), 721(1), 77-85
CODEN: JCBBEP; ISSN: 0378-4347
PB Elsevier Science B.V.
DT Journal
LA English
RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 90 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1999:5893 CAPLUS
DN 130:206764

TI Targeting the tumor vasculature with combretastatin A-4 disodium
phosphate: effects on radiation therapy
AU Li, Lingyun; Rojiani, Aryn; Siemann, Dietmar W.
CS Department of Pharmacology and Experimental Therapeutics, Shands Cancer
Center, University of Florida, Gainesville, FL, 32610, USA
SO International Journal of Radiation Oncology, Biology, Physics (1998),
42(4), 899-903
CODEN: IOBPD3; ISSN: 0360-3016
PB Elsevier Science Inc.
DT Journal
LA English
RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 91 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1999:5892 CAPLUS
DN 130:231998
TI The effect of combretastatin A-4 disodium phosphate in a C3H mouse mammary
carcinoma and a variety of murine spontaneous tumors
AU Horsman, Michael R.; Ehrnrooth, Eva; Ladekarl, Morten; Overgaard, Jens
CS Danish Cancer Society, Department of Experimental Clinical Oncology,
Aarhus University Hospital, Aarhus, DK-8000, Den.
SO International Journal of Radiation Oncology, Biology, Physics (1998),
42(4), 895-898
CODEN: IOBPD3; ISSN: 0360-3016
PB Elsevier Science Inc.
DT Journal
LA English
RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 92 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1999:5891 CAPLUS
DN 130:204769
TI Effects of combretastatin on murine tumors monitored by 31P MRS, 1H MRS
and 1H MRI
AU Maxwell, R. J.; Pharm, B.; Nielsen, F. U.; Breidahl, T.;
Stodkilde-Jorgensen, H.; Horsman, M. R.
CS Gray Laboratory Cancer Research Trust, Northwood, HA6 2JR, UK
SO International Journal of Radiation Oncology, Biology, Physics (1998),
42(4), 891-894
CODEN: IOBPD3; ISSN: 0360-3016
PB Elsevier Science Inc.
DT Journal
LA English
RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 93 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1998:301433 CAPLUS
DN 129:36213
TI Antineoplastic agents. 389. New syntheses of the combretastatin A-4
prodrug
AU Pettit, George R.; Rhodes, Monte R.
CS Cancer Research Institute and Department of Chemistry, Arizona State
University, Tempe, AZ, 85287-2404, USA
SO Anti-Cancer Drug Design (1998), 13(3), 183-191
CODEN: ACDDEA; ISSN: 0266-9536
PB Oxford University Press
DT Journal
LA English
RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 94 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1998:253141 CAPLUS
 DN 128:230173
 TI Antineoplastic Agents. 379. Synthesis of Phenstatin Phosphate
 AU Pettit, George R.; Toki, Brian; Herald, Delbert L.; Verdier-Pinard, Pascal; Boyd, Michael R.; Hamel, Ernest; Pettit, Robin K.
 CS Cancer Research Institute and Department of Chemistry, Arizona State University, Tempe, AZ, 85287-1604, USA
 SO Journal of Medicinal Chemistry (1998), 41(10), 1688-1695
 CODEN: JMCMAR; ISSN: 0022-2623
 PB American Chemical Society
 DT Journal
 LA English
 RE.CNT 53 THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 95 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1997:335437 CAPLUS
 DN 127:60262
 TI Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature
 AU Dark, Graham G.; Hill, Sally A.; Prise, Vivien E.; Tozer, Gillian M.; Pettit, George R.; Chaplin, Dai J.
 CS Tumour Microcirculation Group, Gray Laboratory Cancer Research Trust, Mount Vernon Hospital, Northwood, HA6 2JR, UK
 SO Cancer Research (1997), 57(10), 1829-1834
 CODEN: CNREA8; ISSN: 0008-5472
 PB American Association for Cancer Research
 DT Journal
 LA English
 RE.CNT 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 96 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1996:616598 CAPLUS
 DN 125:309027
 TI Combretastatin A-4 prodrug
 IN Pettit, George R.
 PA Arizona State University, USA
 SO U.S., 7 pp.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5561122	A	19961001	US 1994-363406	19941222
PRAI	US 1994-363406		19941222		

L3 ANSWER 97 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1996:108637 CAPLUS
 DN 124:260682
 TI Synthesis of water-soluble prodrugs of the cytotoxic agent combretastatin A4
 AU Bedford, Simon B.; Quarterman, Charmaine P.; Rathbone, Daniel L.; Slack, John A.; Griffin, Roger J.; Stevens, Malcolm F. G.
 CS Aston Molecules Ltd., Birmingham, B7 4EJ, UK
 SO Bioorganic & Medicinal Chemistry Letters (1996), 6(2), 157-60
 CODEN: BMCLE8; ISSN: 0960-894X
 PB Elsevier

DT Journal
LA English

L3 ANSWER 98 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1995:661775 CAPLUS
DN 123:227731
TI Antineoplastic agents. 322. Synthesis of combretastatin A-4 prodrugs
AU Pettit, George R.; Temple, Carroll, Jr.; Narayanan, Ven L.; Varma, Ravi;
Simpson, Michael J.; Boyd, Michael R.; Rener, Gregory A.; Bansal, Namita
CS Cancer Research Institute and Department of Chemistry, Arizona State
University, Tempe, AZ, 85287-1604, USA
SO Anti-Cancer Drug Design (1995), 10(4), 299-309
CODEN: ACDDEA; ISSN: 0266-9536
PB Oxford University Press
DT Journal
LA English

L3 ANSWER 99 OF 99 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1993:101642 CAPLUS
DN 118:101642
TI Preparation of combretastatin A4 analogs as neoplasm inhibitors
IN Rathbone, Daniel Lee; Slack, John Alfred; Griffin, Roger John; Quarterman,
Charmaine Paulina
PA Aston Molecules Ltd., UK
SO PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 9216486	A1	19921001	WO 1992-GB498	19920319
	W: AU, CA, JP, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE				
	AU 9213719	A1	19921021	AU 1992-13719	19920319
PRAI	GB 1991-6177		19910322		
	WO 1992-GB498		19920319		
OS	MARPAT 118:101642				